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MTORC1 SIGNALING IN MEMORY FORMATION AND DYSFUNCTION 
Natalia Sabrina Rozas de O’Laughlin, B.S. 
Supervisory Professor: Pramod K.  Dash, Ph.D. 
ABSTRACT 
 
The mechanistic Target of Rapamycin Complex 1 (mTORC1) pathway 
integrates cellular availability of growth factors, energy and amino acids to regulate 
protein synthesis and autophagy.  The mTORC1 pathway has also been shown to be 
required for memory consolidation, and its dysregulation is associated with many 
neurological disorders.  MTORC1 is negatively regulated by the tuberous sclerosis 
complex (TSC1/2).  When ATP and growth factors are available, TSC1/2 is inhibited 
and mTORC1 activity can be restored.  In a complementary regulatory pathway, amino 
acids signal to mTORC1 through the Rag GTPases and Ragulator complex, which 
modulate the translocation of mTORC1 from the cytoplasm to the lysosomal surface 
where activation occurs.  This thesis investigates the role of mTORC1 in memory 
formation and dysfunction. 
It has been shown that in response to traumatic brain injury (TBI), mTORC1 
activity is acutely increased, and treatment with rapamycin, a specific inhibitor of 
mTORC1, has been shown to improve outcome.  On the other hand, chronic elevated 
levels of mTORC1 are required for axonal regeneration of injured peripheral nerves 
and increased synapse growth after TBI.  These results suggest that this mTORC1 
could be a potential therapeutic target for TBI patients, but it remains unclear whether 
inhibition or activation of mTORC1 would improve outcome.  Using a TSC2 knock-out 
ix 
 
mouse model we investigated the effects of elevated mTORC1 activity on outcome 
using hippocampal-dependent learning and memory tasks.  My results suggest that 
acute overactivation of mTORC1 impairs long-term memory after brain injury and its 
return to baseline is associated with recovery.  These results could aid in the design of 
treatments for brain-injured patients that differentially target the mTORC1 pathway in a 
temporally specific manner following brain trauma. 
In vitro studies have shown that the amino acid glutamine decreases, while 
leucine increases, mTORC1 signaling in amino acid deprived cells.  However, it 
remains unclear if glutamine and leucine would be effective in vivo at modulating 
mTORC1 signaling in the brain in order to influence cognition.  My results show that in 
vivo intrahippocampal infusions of glutamine inhibited mTORC1 signaling and 
impaired memory formation, effects that were reversed by the co-administration of 
leucine.  Furthermore, oral administration of glutamine to conditional knock-out mice 
lacking the Tsc2 gene prolonged their survival.  Taken together, these findings indicate 
that glutamine can decrease brain mTORC1 activity, and may have utility in the 
treatment of neurological problems associated with elevated mTORC1 signaling. 
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CHAPTER 1 
Introduction 
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THE MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY 
 
Humans have searched nature for medicinal products for at least 5000 years 
(152).  Discovering new drugs to treat incurable diseases and improve health drives 
the quest to find new organic compounds from plants, bacteria, fungi or animals even 
today.  The story of the mechanistic Target of Rapamycin (mTOR) starts with a 
Canadian expedition to Easter Island in the 1960s.  This excursion’s goal was to 
collect soil and plant samples to be analyzed later for drug discovery (122).  
Fortuitously, the bacterium Streptomyces hygroscopicus was found in one of these soil 
samples.  This bacterium produces a secondary metabolite with strong antifungal 
properties.  Researchers decided to name this metabolite “Rapamycin” in honor of the 
place it was found1 (173, 194).   
Interestingly, the original anti-fungal property of rapamycin turned out to be only 
one of its many potential uses.  Rapamycin earned a special appreciation as an 
immunosuppressant and anti-cancer drug due to its capacity to inhibit cell growth and 
division.  However, a target of rapamycin was yet to be found (75, 129).  Sixteen years 
after the first rapamycin research publications, a group of scientists in Switzerland 
discovered the first evidence for the molecular targets of rapamycin.  They searched 
for spontaneous yeast mutants able to grow in concentrations of rapamycin known to 
halt cellular division.  Two mutants were found with dominant resistance to rapamycin 
and researches designated them Target of Rapamycin 1 (TOR1) and TOR2.  These 
genes were later cloned and sequenced to discover that they encoded 
phosphatidylinositol-like kinases (16, 108).  A year later, the mammalian homologue 
                                            
1
 “Rapa Nui” means Easter Island in the native language and “mycin” is the latin form to name 
drugs derived from a fungus-like bacteria 
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TOR protein was described (13, 163).  It is now known that TOR kinases are 
conserved in most eukaryotes, with metazoans carrying only one TOR gene.  We also 
know that even though they resemble phosphatidylinositol kinases, they are truly 
serine/threonine protein kinases.  Results from the last 20 years of TOR research 
suggest that this pathway impacts many critical cellular functions, including playing a 
leading role in the regulation of cell growth and proliferation.  These functions have 
associated TOR signaling with memory consolidation and plasticity.  Furthermore, the 
observation that TOR signaling is dysregulated in many human diseases, including 
neurological disorders, has motivated the search for ways to modulate activity of this 
pathway and inspired this thesis work.  In this chapter, I will review our current 
understanding of TOR signaling, with an emphasis on its role in memory function and 
dysfunction. 
 
MTOR kinase is part of the mTOR complex 1 signaling pathway 
 
The mTOR kinase can be part of two distinct complexes: mTOR complex 1 
(mTORC1) and mTORC2.  These two complexes differ from each other in their 
sensitivity to rapamycin, regulation by upstream signals and downstream targets and 
biological effects.  Acute rapamycin treatment inhibits mTOR when it is part of 
mTORC1 but not mTORC2 (83, 123).  The lack of a specific inhibitor of mTORC2 has 
limited the knowledge about this pathway.  It is known that growth factors act as 
upstream regulators of mTORC2, but their mechanism of action and whether other 
signals regulate this pathway is not known (154).  MTORC2 regulates cell survival and 
cytoskeletal organization through its action on Akt (also known as protein kinase B) 
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and protein kinase Cα respectively.  Akt is an important oncogene mutated in several 
types of cancers and mTORC2 plays a major role in its phosphorylation and activation.  
In addition, the role of mTORC2 in mediating cytoskeletal organization has implicated 
this pathway in tumor cell motility and metastasis (168, 210).  Recently, it was shown 
that mTORC2 is involved in memory formation.  A conditional brain deletion of a key 
protein found in mTORC2 decreased actin polymerization in the hippocampus and 
impaired long-term memory (LTM) and late-phase hippocampal long-term potentiation 
(L-LTP) (78).  MTORC1, on the other hand, integrates several cellular signals derived 
from growth factor, energy and nutrient availability to regulate macromolecule 
biosynthesis, autophagy and energy metabolism.  The role of mTORC1 in regulating 
protein synthesis suggests this pathway influences neuronal plasticity and memory 
formation (26).  In addition, its role as an autophagy inhibitor has associated mTORC1 
with several neurodegenerative disorders (22, 23).  In the remaining sections I will 
focus my attention on the mTORC1 pathway.   
The mTOR protein is a serine/threonine kinase belonging to the 
phosphoinositide 3-kinase (PI3K)-related kinase family.  Composed of 2549 amino 
acids, mTOR contains five major domains (Fig 1.1) (112).  Near the N-terminus, there 
are several HEAT repeats (present in: Huntingtin, Elongation factor 3, protein 
phosphatase 2A, TOR), which are thought to act as flexible scaffolding for other 
proteins to attach.  Indeed, a protein named regulatory-associated protein of mTOR 
(raptor) binds mTOR at the HEAT domain to regulate assembly, localization and 
substrate binding to mTORC1.  Raptor is one of the defining components of mTORC1, 
by interacting with certain substrates that contain a TOR signaling motif; it determines 
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the specificity of mTORC1 (63, 97).  mTOR also contains two domains found in all 
PI3K-related protein subfamilies: a FAT domain (present in PI3K-related protein  
 
 
 
Figure 1.1: Components of mTORC1 in relation to mTOR protein domain structure.  
mTOR protein (blue) depicting its five major domains: HEAT, FAT, FRB, Kinase and 
FATC.  The mTOR protein together with raptor, deptor, mLST8, PRAS40, tti1 and tel2 
form the mTOR complex 1.  The Rapamycin-FKBP12 complex specifically interacts 
with mTOR and acutely inhibits it only when it is part of mTORC1. 
 
subfamilies: FRAP, ATP, TRRAP) and a FATC domain (FAT COOH-terminus) which 
are essential for kinase function (12, 181).  It is thought that FAT and FATC interact in 
a way in which they can expose the catalytic domain.  Supporting this view, deptor 
(DEP domain-containing mTOR-interacting protein) acts as an inhibiting regulator of 
mTORC1 and binds mTOR through the FAT domain (151).  The mechanism by which 
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rapamycin inhibits mTORC1 is not yet fully understood, but it is known that the 
intracellular FK506-binding protein (FKBP12) first binds rapamycin, and then together 
they interact and inhibit mTOR through its FKBP12-rapamycin-binding domain (FRB) 
(13, 163).  Finally, the mTOR kinase domain shares some sequence similarity to PI3K, 
though it is functionally distinct, as it confers serine/threonine specific, rather than 
phosphatidylinositol, kinase activity. 
Seven core proteins are known to compose mTORC1: mTOR, raptor, deptor, 
proline-rich AKT substrate of 40kDa (PRAS40) and SEC13 protein 8 (mLST8), 
telomere maintenance 2 (tel2) and Tel2-interacting protein (tti1) (112).  Studies 
suggest that PRAS40, like deptor, acts as an mTORC1 inhibitor.  Both PRAS40 and 
deptor are also substrates for mTOR kinase, and when phosphorylated by active 
mTOR, their association with the complex is weakened, promoting further mTOR 
kinase activity (167, 186, 193, 196).  The role of mLST8 is still unclear since its 
deletion has no effect on mTORC1 activity (59, 98).  When Tti1 and tel2 are depleted, 
mTOR complex formation and stability is impaired suggesting they may play a role as 
scaffolding proteins (94).  The wide range of processes that mTORC1 regulates 
suggests it may be reasonable to think that additional proteins that interact with 
mTORC1 are yet to be found.  The identification of novel proteins associated with 
mTORC1 could aid our understanding by providing insights into mTORC1 target 
specificity, function and regulation. 
 
 
 
7 
 
Upstream regulation of mTORC1 
 
Most cellular signals that reach mTORC1 are known to travel through either of 
two ways: growth factors and ATP levels through the tuberous sclerosis complex 1/2 
(TSC1/2), or amino acids through the Rag GTPases.  Directly upstream of mTOR, Ras 
homologue enriched in brain GTPase (Rheb) interacts and strongly stimulates 
mTORC1 activity.  TSC1/2, a GTPase activating protein (GAP) complex, formed by 
tuberous sclerosis complex 1 (TSC1 also called hamartin), TSC2 (also called tuberin) 
and Tre2-Bub2-Cdc16 (TBC), is responsible for converting Rheb into its inactive GDP-
bound state (36, 53, 124).  Therefore, when upstream input is lacking, TSC1/2 keeps 
Rheb in its GDP-bound state and mTORC1 is inhibited (Figure 1.2A).  Growth factors, 
stress signals, oxygen and energy levels are sensed through a vast network of 
signaling pathways that converge on TSC1/2.  For instance, insulin (a nutrient signal 
produced in response to increased blood glucose levels) can bind to receptor tyrosine 
kinases on the cell surface and activate the PI3K-Akt pathway which leads to TSC1/2 
inactivation and subsequent mTORC1 activation by GTP-bound Rheb.  Other growth 
factors follow a similar pathway to reach mTORC1 or signal through the Ras-Erk 
pathway instead (37).  Energy status, by way of a change in the AMP:ATP ration, can 
be sensed by the AMP-dependent protein kinase (AMPK).  When AMPK is active, it 
phosphorylates and activates TSC1/2 to inhibit mTORC1 activity (34, 150).  
Altogether, mTORC1 is a major regulator of anabolic processes that receives most 
cellular inputs regarding energy and nutrient availability through TSC1/2.   
Amino acids also play a major role in mTORC1 signaling.  In their absence, 
growth factor and energy signals are unable to activate mTORC1.  In vitro studies  
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Figure 1.2: Upstream regulation of mTORC1.  A) Amino acid insufficiency fails to 
activate v-ATPase and ragulator.  These networks are involved in the activation and 
anchoring of the Rag proteins to the lysosomal membrane.  RagA/B remain in their 
GDP-bound forms unable to bind mTORC1 for translocation to the lysosomal 
membrane where Rheb is located.  A lack of cellular nutrient and energy availability 
promote the activation of TSC1/2 which inhibits Rheb through its GAP activity.  GDP-
bound Rheb is unable to interact with mTORC1 to stimulate its kinase activity.  B) 
Upon growth factor availability and increased ATP levels, TSC1/2 becomes repressed 
and consequently its inhibition on Rheb is terminated.  GTP-bound Rheb is then ready 
to interact and promote mTORC1 activity.  However, amino acids are required to 
promote v-ATPase and ragulator, which in turn activate and anchor Rag proteins to 
the lysosomal membrane bringing mTORC1 to the site for Rheb to complete its 
activation. 
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suggest that mTORC1 is exceptionally sensitive to the levels of certain amino acids, 
particularly leucine, arginine and glutamine.  Although an intracellular amino acid 
sensor has yet to be identified, it has been shown that the Ragulator complex and Rag 
GTPases (RagA, B, C and D) play an important role in this process (85).  Rag 
GTPases are small G proteins able to form heterodimers: RagA or B with RagC or D.  
These heterodimers have been found to have opposite nucleotide loading states.  
When amino acids are absent RagA/B is GDP-bound and RagC/G is GTP-bound, this 
makes the complex inactive. Rag GTPases seem to work in parallel to Rheb and upon 
amino acid availability; RagA/B become GTP-bound (And RagC/D GDP-bound).  This 
is promoted by the Ragulator complex, which acts as a guanine nucleotide exchange 
factor for RagA and B and promotes GDP release for subsequent loading with GTP 
(Figure 1.2A and B) (99, 165, 166).  While growth factors and energy signals converge 
at TSC1/2, to regulate Rheb, amino acids stimulate Ragulator and Rag GTPases to 
induce the translocation of mTORC1 from the cytoplasm to the lysosomal surface.  
Interestingly, the lysosomal surface is one of the places where active Rheb can be 
found.  Constitutive expression of GTP-bound RagA and B, which anchor mTORC1 
near Rheb, make mTORC1 activation resistant to amino acid starvation (165).  This 
supports the current thinking that the coordinated shift of mTORC1 localization 
towards Rheb ensures mTORC1 activation only when amino acids are available. 
Therefore, one could potentially inhibit mTORC1 signaling through either of these two 
parallel mechanisms: TSC1/2 or Rag-Ragulator networks. 
Recent studies have focused their attention on the characterization of Vacuolar 
H+-ATPase (v-ATPase) and its role in mTORC1 regulation upon amino acid 
availability.  v-ATPase is found in the lysosomal membrane and pumps protons into 
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the organelle to decrease pH.  Interestingly, v-ATPase interacts with both the ragulator 
complex and Rag proteins under conditions of amino acid starvation.  An increase in 
amino acids (intracellular and/or extracellular) leads to their accumulation inside the 
lysosome and communicates to v-ATPase ultimately leading to mTORC1 activation.  
This has been suggested as the “inside-out” mechanism of amino acid regulation of 
mTORC1 (211).  Whether v-ATPase can directly sense amino acids is not known.  
Leucine and Arginine are known to be the best mTORC1 activators, since depriving 
cells from either one of them closely resembles complete amino acid starvation (65).  
These amino acids likely signal to mTORC1 through the Rag-Ragulator pathway 
although the mechanism by which cells sense these amino acids is not fully 
understood.  Leucyl-tRNA synthetase (LeuRS) has been suggested as a potential 
leucine sensor.  LeuRS is a cytoplasmic protein that can catalyze the ATP-dependent 
ligation of L-leucine to the corresponding tRNA.  When leucine is available, LeuRS 
translocates to the lysosomal membrane and can act as a GAP for RagD (11, 62).  
However, in contrast to the “inside-out” model for amino acid detection, LeuRS senses 
leucine availability in the cytoplasm.  Further studies will be needed to understand if, 
and how, these two leucine sensing models cooperate to regulate mTORC1. 
Glutamine is a non-essential amino acid abundant in the blood stream and 
involved in several biological functions critical for cell growth.  Glutamine can enter the 
Krebs cycle by producing α-ketoglutarate through glutaminolysis.  It is also 
incorporated into proteins during translation and is necessary for amino acid, fatty acid 
and nucleotide synthesis.  Glutamine participates in the glutamine-glutamate-GABA 
cycle, thus playing an important part in neurotransmitter recycling in the brain.  
Interestingly, glutamine has also been shown to modulate mTORC1 activity, although 
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the mechanisms of action are not fully understood (102).  It has been proposed that 
glutamine is a key component of leucine-induced mTORC1 activation.  When cultured 
HeLa cells are deprived of amino acids, adding only the essential amino acids back 
into the culture media does not fully activate mTORC1.  When both, essential amino 
acids and glutamine, are incorporated to the culture they synergize to stimulate 
mTORC1.  Systematic inhibition of the amino acid transporters SLC1A5 and SLC7A5 
led Nicklin et al. to propose a mechanism by which intracellular glutamine is 
exchanged for extracellular leucine to activate mTORC1 (140).  This finding was 
independent of glutamine derived-glutamate or α-ketoglutarate, suggesting that 
glutamine acts as a free amino acid to indirectly modulate mTORC1.  However, this 
does not seem to be the only mechanism for mTORC1 activation by glutamine.  
Inhibition of glutaminolysis was shown to reduce GTP-RagB, which in turn blocked 
mTORC1 translocation to the lysosome and activation in response to glutamine and 
leucine (39).  Furthermore, addition of an α-ketoglutarate analogue restored mTORC1 
translocation and its subsequent activation (39).  Interestingly, during glucose and 
glutamine starvation, adding Krebs cycle intermediates (α-ketoglutarate from 
glutamine, pyruvate from glucose) can restore mTORC1 activation through an AMPK 
and Rag independent pathway.  The model proposed suggests that the scaffolding 
proteins tti1 and tel2, together with tti2 and RuvB-like1 and 2, form a complex that 
requires ATP to assemble and stabilize mTORC1 (103).  In summary, glutamine 
appears to be able to indirectly regulate mTORC1 as a free amino acid promoting 
leucine intake, or by providing Krebs cycle metabolites (called anaplerosis) through 
glutaminolysis.   
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Cells live in a complex nutritional environment that is in constant flux, mTORC1 
is a key pathway able to integrate these signals in a timely manner to regulate 
necessary anabolic processes.  Although significant progress has been made towards 
understanding the complexity of mTORC1 signaling, important questions remain 
unanswered.  For example, experiments investigating amino acid regulation of 
mTORC1 have been performed in starved cells that are systematically re-fed to 
observe changes in biochemical interactions.  Complete cellular and tissue starvation 
is an unlikely situation when studying whole living organisms.  One hypothesis to 
examine would be, if amino acid starvation and re-feeding strongly modulates 
mTORC1 activity, then partial removal or addition of amino acids will regulate 
mTORC1 in a graded manner.  The confirmation of this hypothesis would suggest that 
amino acids could have the potential to act not only as building blocks for proteins, but 
also as signaling molecules.  Moreover, understanding how different amounts of amino 
acids finely modulate mTORC1 signaling could aid in the design of dietary treatments 
for diseases in which this pathway becomes dysregulated. 
 
MTORC1 downstream effects 
 
When mTORC1 integrates information about the nutritional and energy status 
of the cell, it is able to regulate major pathways leading to cellular growth and 
proliferation.  The best characterized process regulated by mTORC1 is protein 
synthesis.  Translation consumes a great amount of nutrients and energy, and its 
regulation is necessarily tied to mechanisms that are able to sense the cellular 
environment for sources of nourishment.  MTORC1 is one such mechanism, able to 
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control protein synthesis through its kinase activity by direct or indirect phosphorylation 
events.   
Translation initiation starts when the small ribosome subunit is recruited to the 
5’ end of the mRNA.  This recruitment is accomplished by eukaryotic translation 
initiation factor 4E (eIF4E), a cap binding protein that binds the mRNA and promotes 
the formation of the pre-initiation complex (eIF4F complex) containing eIF4E, eIF4G 
(scaffold protein) and eIF4A (RNA helicase).  This complex recruits the small 
ribosomal subunit to the mRNA to start scanning for the start codon.  Once found, the 
complete ribosome is assembled to begin polypeptide formation (54).  MTORC1 
primarily regulates 5’ terminal oligopyrimidine (TOP) mRNAs through 4E(eIF4E)-
binding protein 1 (4E-BP1).  4E-BP1 is a translation initiation repressor that binds 
eIF4E and prevents complex assembly.  MTORC1 promotes translation by 
phosphorylating and inhibiting 4E-BP1, thus enabling translation initiation (Fig 1.3A) 
(64, 64, 65, 65, 187).  A second well characterized target of mTORC1 is S6 kinase 
(S6K).  When mTORC1 phosphorylates and activates S6K, they work in concert to 
promote assembly of the translation pre-initiation complex (Fig 1.3A).  For instance, 
S6K phosphorylates eIF4B, a co-factor that enhances eI4FA helicase activity 
necessary for translation initiation of double stranded 5’ untranslated regions of the 
mRNA.  S6K is able to phosphorylate and target for degradation programmed cell 
death 4 (PDCD4), which inhibits eiF4A helicase activity (126, 130).  S6K has also 
been suggested to have a role in ribosome biogenesis thereby helping translation 
efficiency (84).  The ribosomal protein S6 (S6) was the first described target of S6K.  It 
is a component of the small ribosomal subunit and has been extensively used to study 
mTORC1 activity even though its role in protein translation remains unclear (126, 127).  
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Protein synthesis is a paramount cellular process regulated throughout life.  It plays 
major roles in embryonic development, normal physiology maintenance and memory 
formation.  MTORC1 is a key pathway involved in translation activation upon nutrient 
and energy availability making it an attractive pathway to study in diseases in which 
polypeptide biogenesis is deregulated.   
 
 
 
 
Figure 1.3: Simplified mTORC1 regulation of translation and autophagy.  A) MTORC1 
kinase directly phosphorylates 4E-BP1 inhibiting its repression of translation initiation.  
It also phosphorylates S6K to promote protein synthesis in several ways, including 
translation initiation complex formation.  Levels of phosphorylated S6 are commonly 
used as an indirect measure of mTORC1 activity.  B) Active mTORC1 phosphorylates 
ULK1 and Atg13 preventing their association for autophagosome formation. 
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 The synthesis of lipids, upregulation of cellular metabolism and ATP production 
are also anabolic processes that are influenced by mTORC1.  These anabolic 
processes are regulated by transcription factors which, in turn, are controlled directly 
or indirectly by mTORC1.  For example, the sterol regulatory element-binding 
protein1/2 (SREBP1/2) transcription factors control the expression of many genes 
necessary for the synthesis of fatty acids and cholesterol.  Inhibition of mTORC1 
prevents SREBP1/2 translocation to the nucleus and decreases the translation of 
lipogenic genes (40, 111, 156).  Similarly, mTORC1 activates the transcription and 
translation of glycolytic gene regulators like Hypoxia inducible factor 1α (14, 79).   
 Cellular growth can be promoted both by positive regulation of anabolic 
processes or inhibition of catabolic processes.  MTORC1 is also involved in the 
repression of macroautophagy (here referred to as autophagy).  Autophagy is the main 
mechanism by which cells degrade dysfunctional components, such as organelles and 
proteins, via lysosomes.  The cell loads lysosomes through the formation and transport 
of intracellular membrane vesicles called autophagosomes.  In normal conditions, 
basal levels of autophagy are responsible to help maintain cellular homeostasis by 
recycling long-lived or damaged proteins and organelles.  Autophagy levels can 
increase in response to cellular stress, including starvation and growth factor 
withdrawal.  Similar to the regulation of protein synthesis, autophagy initiation is tightly 
regulated to prevent unnecessary removal of healthy proteins but to rapidly react to 
stress and degrade harmful components.  In mammalian cells, the initiation complex of 
the autophagy cascade contains Unc-51 Like autophagy activating Kinase 1 (ULK1), 
Autophagy related 13 (Atg13) and RB1-inducible coiled-coil protein 1 (RB1CC1), 
together making up the ULK1 complex (93, 203).  Under normal conditions, ULK1 and 
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Atg13 are phosphorylated on multiple sites that become dephosphorylated under 
starvation conditions.  Several studies have shown that mTORC1 phosphorylates 
ULK1 and Atg13 (Fig 1.3 B).  These phosphorylation events correlate with autophagy 
inhibition and lower ULK1 kinase activity.  Additionally, rapamycin treatment reduces 
the levels of phosphorylated ULK1 and Atg13 and increases ULK1 activity (52, 73, 93, 
203).  These studies suggest that mTORC1 is a key regulator of autophagy.   
 The mTORC1 complex has been linked to a wide range of disorders including 
neurodegenerative disorders, traumatic brain injury (TBI), tuberous sclerosis complex 
(TSC), age-related pathologies and metabolic diseases (38, 112, 128).  The 
involvement of mTORC1 in several conditions is not surprising given that this pathway 
is an important regulator of some of the most basic and necessary cellular functions.  
Our understanding of mTORC1 signaling is still incomplete, but what is known can 
guide future research to understand how different deregulated components give rise to 
diverse diseases. 
 
MTORC1 AND MEMORY FORMATION 
 
Memory is one of the most complex mental processes in our body and can 
define an individual.  One of the biggest challenges of biology has been to understand 
how different brain systems, cellular networks and molecular signaling pathways 
interact together to encode, store and retrieve memories.  More than 100 years ago, 
two German scientists, Müller and Pilzecker, proposed the idea that memories took 
time to be fixed.  They called this process consolidation.  They also suggested that 
transient activity in the brain, acting as perseverations of the task being learned, was 
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necessary for establishing representations and strengthening the associative memory 
(113, 136).  Around the same time, there was already a notion of short-term memories 
(STM) and long-term memories (LTM).  These concepts impacted Hebb’s seminal 
theory in which he proposed that repeated excitation of one neuron onto a second, 
would produce growth or metabolic changes conveying the first neuron the ability to 
excite the second more efficiently (69).  Hebb proposed that new memories were 
represented in “reverberating circuits”, the storage for STM.  After enough 
reverberations, these STM would consolidate into LTM.  Hebb’s idea of changes 
happening between neurons inspired the next generation of researchers to test 
possible molecular mechanisms responsible for these alterations (113, 137).  A 
popular strategy to elucidate some of the molecular pathways involved in synaptic 
changes after memory formation has been to deliver different treatments immediately 
after training.  This approach can selectively target consolidation without altering either 
acquisition or retrieval of memory.  Early on, protein synthesis was found to be critical 
for memory consolidation.  Intracranial injections of puromycin (a protein synthesis 
inhibitor) were shown to impair memory.  It was also revealed that inhibition of memory 
formation was possible only within a certain window of time after learning (9, 45, 177).   
It is now known that memory can be divided into short-term memories, lasting 
minutes to hours, and long-term memories lasting for years.  Short-term memories do 
not depend on protein synthesis, while long-term memories do.  Several different 
studies have shown the importance of individual translational proteins in LTM 
formation.  For instance, when the interaction between components of the translation 
initiation complex, eIF4E and eIF4G is disrupted in the amygdala, long-term fear 
memory is impaired (72).  Furthermore, genetically engineered mice lacking S6K show 
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impaired learning and memory in diverse behavioral tasks including fear conditioning, 
taste aversion and Morris water maze (7).  It is then intuitive to think that mTORC1 
also plays a role in the regulation of LTM through its ability to facilitate polypeptide 
synthesis.  Indeed, Casadio et al.  showed that rapamycin impaired long-term 
facilitation in Aplysia neurons (18).  Later studies confirmed that inhibition of mTORC1 
signaling, also utilizing rapamycin, could disrupt long-term memories in mammals (31, 
183, 188).  In addition, LTM and L-LTP are associated with increased levels of 
mTORC1 activity measured by downstream targets (including phospho-4E-BP1 and 
phospho-S6K, and phospho-S6) (17, 175, 190). 
Links between upstream regulators of mTORC1, such as growth factors and 
energy levels, have also been shown to affect LTM.  For instance, intra-hippocampal 
infusions of glucose were shown to correlate with decreased AMPK activity, increased 
mTORC1 activity and enhanced memory formation (31).  On the other hand, inhibition 
of AMPK with the AMP mimetic drug AICAR, activates AMPK, represses mTORC1 
signaling and impairs LTM in rats and L-LTP in mouse hippocampal slices (31, 157).  
In addition, brain-derived-neurotrophic-factor (BDNF) has been shown to induce 
mTORC1 activation and translation in neuronal dendrites.  This suggests that 
mTORC1 is also present at synaptic terminals and could contribute to the activation of 
local protein synthesis required for L-LTP (95, 182).  Amino acid modulation of 
memory formation has not been fully explored.  Acute intra-hippocampal 
administration of leucine and chronic administration of branched-chain amino acids 
(BCAA: leucine, isoleucine, valine) impair memory in a manner suggested to resemble 
Maple syrup urine disease (56, 169).  Intra-cranial injections of glutamine impair 
memory formation in the chick but oral administration improves it in rats (55, 86).  
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These variable results stem from the diversity of animal models, modes of amino acid 
administration and lack of knowledge about the mechanisms involved.  Nevertheless, 
the role leucine and glutamine play in mTORC1 signaling suggests that their fine 
modulation could have significant effects in LTM.   
Understanding the individual events upstream and downstream of mTORC1 
and their role in LTM is of great importance to elucidate the complex interaction that 
takes place in living organisms to form memories.  This knowledge is also crucial to 
develop specific approaches to treat diseases in which mTORC1 dysregulation causes 
neuropsychological impairments. 
 
MTORC1 AND MEMORY DYSFUNCTION 
 
MTORC1 presence throughout the nervous system, together with its ability to 
regulate key processes required for cellular growth and proliferation; make this 
pathway crucial for preserving neuronal health.  After nervous system trauma, 
mTORC1 activity can become highly upregulated (20, 25).  Whether this upregulation 
of mTORC1 exacerbates or improves cognitive outcome is not well understood (38, 
96).  Following spinal cord injury, exercise-induced or ATP-induced mTORC1 
activation correlates with increased plasticity and locomotor function recovery (76, 
119).  Additionally, mTORC1 activation is required for axonal regeneration of adult 
retinal ganglion cells and corticospinal neurons after injury (120, 148).  However, 
traumatic brain injury (TBI) studies suggest that mTORC1 inhibition with rapamycin 
improves functional recovery and decreases posttraumatic epilepsy (44, 60, 147).  
Parkinson’s disease, Alzheimer’s disease and stroke have also been associated with 
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misregulation of mTORC1.  Similarly, findings seem contradictory with some studies 
suggesting mTORC1 inhibition could be a strategy against these disorders and others 
pointing out that its activation instead would be beneficial for treatment (22, 128).  The 
disagreements in the literature are not unexpected considering that mTORC1 
regulates and balances two opposing processes: protein synthesis and degradation.  
Understanding how mTORC1 is finely modulated in normal conditions would aid in the 
design of treatments for this disorders.   
One disease where the role of mTORC1 is better defined is tuberous sclerosis 
complex (TSC).  TSC is an autosomal dominant disorder arising from a heterozygous 
mutation in either TSC1 or TSC2 (1, 192).  TSC patients develop benign tumors 
throughout the body (hamartomas), including the brain, and cognitive decline can 
range from moderate to severe.  A graded loss of TSC1 or TSC2, which causes 
overactive mTORC1, could be the cause of learning and intellectual disabilities 
manifested in TSC patients (205).  However, loss of heterozygocity as the mechanism 
by which hamartomas form in the brain could also cause behavioral abnormalities (58, 
70).  Despite the lack of mechanistic detail in our understanding of TSC, it is clear that 
mTORC1 dysregulation plays a key role in its pathogenesis.  Accordingly, mTORC1 
inhibitors are being studied as potential treatments for TSC and everolimus, a 
derivative of rapamycin, has been approved by the FDA for the treatment of TSC 
associated subependimal giant cell astrocytomas (15, 42, 48).   
MTORC1 plays a role in long-term memory formation through its ability to 
positively regulate protein synthesis.  However, there is a gap in our understanding of 
mTORC1 graded modulation and its effects on memory.  For example, strong 
mTORC1 inhibition with rapamycin impairs memory formation, but TSC, which 
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increases mTORC1 activity, causes cognitive deficits.  These results indicate that 
normal memory is modulated by a defined range of mTORC1 activity.  Future studies 
are needed to fully understand how different upstream mTORC1 regulators affect its 
downstream effects in a concerted manner that allows for a balanced activation of 
mTORC1 in a timely manner.   
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CHAPTER 2 
Materials and methods 
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ANIMALS 
 
All protocols involving the use of animals were in compliance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and were 
approved by the Institutional Animal Care and Use Committee. 
 
Rats 
 
Male Long-Evans rats (250-280 g) were purchased from Charles River 
Laboratories (Wilmington, MA).  Animals were housed two per cage with a red plastic 
tunnel for enrichment.  Rats were kept in a 12 h light/dark cycle, water and fed ad 
libitum.   
 
Tsc2+/- and Tsc2flox/flox; CamK2a-Cre mice 
 
Tsc2+/- and Tsc2flox/flox; CamK2a-Cre (Tsc2CKO) mice were obtained from Dr.  
Michael J.  Gambello’s laboratory.  A Tsc2 mouse allele flanked by loxP sites (floxed) 
was generated by insertion of loxP sites in introns 1 and 4 of the mouse Tsc2 gene 
(Tsc2flox/flox mice) (71).  To generate Tsc2+/- animals, Tsc2flox/flox mice were crossed to a 
mouse strain containing the Cre recombinase gene driven by a Cytomegalovirus 
promoter (CMV-Cre).  CMV-Cre mice are a general Cre-deletor strain expressing Cre 
in all tissues.  The resulting progeny were intercrossed to propagate Tsc2+/- mice.  
Tsc2+/+ siblings were used as controls in my experiments and homozygous Tsc2-/- 
mice are embryonic lethal.  To generate Tsc2CKO mice, Tsc2flox/flox were crossed to 
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Jax mice B6.Cg-Tg (Camk2a-cCre)T29-1Stl/J (Jackson Laboratories, Sacramento, 
CA, mouse strain #005359).  The resulting progeny were intercrossed to propagate 
Tsc2CKO mice which contain a deletion created by Cre-recombinase only in 
hippocampus. 
Mice were kept in a 12 h light/dark cycle, watered and fed ad libitum.  Mating 
cages housed 2 females and 1 male and litters were sexed and genotyped at P10.  At 
P21 litters were separated according to gender and 5 animals housed per cage. 
 
Genotyping: P10 mice were sexed and labeled by a skin punch taken from their ear.  
DNA was extracted from ear tissue and prepared for PCR using REDExtract-N-Amp™ 
Tissue PCR Kit (Sigma-Aldrich, St.  Louis, MO).  To genotype Tsc2+/- and Tsc2+/+ 
mice, two forward primers A- 5’ CCTCCTGCATGGAGTTGAGT 3’ and B- 5’ 
CAGGCATGTCTGGAGTCTTG 3’ and one reverse primer C- 5’ 
GCAGCAGGTCTGCAGTGAAT 3’ were designed to detect a 390 bp PCR product 
from a wild type allele and a 547 bp PCR product corresponding to a shortened gene 
region from where exons 2-4 were excised by Cre (Figure 2.1A and B).  A third 434 bp 
PCR product was also detected corresponding to the floxed allele (Figure 2.1A, B).  A 
second PCR was run to confirm the presence of Cre (219 bp band) and a positive 
control (Receptor associated protein of the synapse, Rapsn, 590 bp band) in 
Tsc2CKO mice (Fig 2.1C). 
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Figure 2.1: Genotyping scheme.  A) Schematic showing the Tsc2 murine gene, 
located in chromosome 17.  The illustration shows the location of inserted loxP sites 
as well as the primers used for genotyping.  There are 3 viable PCR products.  Top, 
exons 2-4 knocked-out by Cre recombinase (547 bp).  Middle, presence of loxP sites 
without excision by Cre (434 bp).  Bottom, wild-type allele (390 bp).  B) Representative 
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DNA gel showing possible alleles in mouse cohorts.  C) Since Cre expression is 
restricted to hippocampal neurons, and ear tissue was used for DNA extraction, 
Tsc2CKO animals required a second PCR to confirm the presence of Cre (219 bp).  
Rapsn was used as a positive control for amplification (590 bp). 
 
CELL CULTURE 
 
Mouse brain endothelial cells, bEnd.3 stock # CRL2299 were purchased from 
American Type Culture Collection (Manassas, VA).  bEnd.3 cells were maintained at 
less than 60%-80% confluence in DMEM (Delbecco’s modified Eagle’s medium, Life 
Technologies) supplemented with 10% fetal bovine serum and penicillin/streptomycin 
(5000 U/5000 µg/ml).  Cells were seeded in tissue-culture treated dishes at 600-800 
cells/cm2 and passed every 3-4.  Passage number and culture confluence were noted 
for each experiment.  Cells used for experimentation were between passages 27-35.   
bEnd.3 cells were grown in DMEM  supplemented with 10% fetal bovine serum 
and penicillin/streptomycin (5000 U/5000 µg/ml).  bEnd.3 cells were seeded in tissue-
culture treated dishes at 2000 cells/cm2.  48 hrs after reaching confluence, cells were 
incubated for 2 h with either serum-free DMEM lacking glutamine or DMEM with serum 
(Life Technologies, Grand Island, NY).  Glutamine (5 mM and 40 mM) (Sigma-Aldrich, 
St.  Louis, MO) or vehicle was then added to the plates (33, 138).  After 30 min, media 
was removed, plates quickly washed with 1X PBS and cells lysed in boiling NuPAGE® 
LDS sample buffer.  Protein concentrations were determined with a NanoOrange 
Protein Quantification Assay (Invitrogen, Carlsbad, CA), using bovine serum albumin 
(BSA) as the standard and samples stored at -20C to be used for western blot 
experiments.   
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SURGICAL PROCEDURES 
 
Closed Head Injury 
 
A single mild closed head injury (mCHI) was delivered to mice essentially as 
previously described (80).  Tsc2+/- and Tsc2+/+ control littermates mice were 
anesthetized with 5% isofluorane in a 1:1 O2/air mixture then maintained with 2.5% 
isofluorane in a 1:1 O2/air via face mask for the remainder of the surgical procedure.  A 
midline incision was made to expose the skull and anesthesia discontinued.  
Immediately after, mice were placed in a foam pad that kept its head level with its 
body.  A pneumatically driven controlled cortical impact (CCI) device with a metal 
impactor tip (5 mm in diameter) was used to deliver a single impact to the skull 
(between lambda and bregma over the sagittal suture).  The impactor was driven at 55 
psi to a depth of 1 mm.  Immediately following impact, apnea was monitored.  When 
breathing returned to normal the scalp was closed with sterile surgical staples.  
Animals were monitored for recovery of tail pinch response and righting response 
(time it takes the animal to right itself from being placed on its back).  Sham animals 
received the same treatment but without the impact. 
 
Hippocampal cannulations and infusions 
 
Hippocampal cannulations were performed as previously described (31).  Rats 
were anesthetized with 4% isoflurane in a 2:1 N2O/O2 mixture and then maintained 
with 2% isoflurane/2:1 N2O/O2 mixture via face mask.  Bilateral guide cannulas aimed 
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at the dorsal hippocampus (anteroposterior, -3.3 mm, lateral, ±2.0 mm from bregma; 
ventral, -2.0 mm from the dura), were implanted.  Then rats were allowed to recover in 
their home cages for 10 days.  Injection cannulas extended 1.75 mm beyond the tips 
of the guides, yielding a total depth of 3.75 mm below the dura.  Sterile L-glutamine 
(194 mM) and L-leucine (137 mM) were prepared in saline before infusion.  All 
injections (1.3-1.5 µl/hippocampus of either drug or saline) were performed in freely 
moving animals at a rate of 0.2 µl/min via dual syringe infusion pump (Stoelting, Wood 
Dale, IL). 
 
Cannula placement 
 
After completion of all behavioral experiments involving animals with implanted 
cannulas, animals were killed and brains quickly removed for histological assessment.  
Brains were cut into 2 mm coronal sections while being bathed in ice-cold artificial 
cerebrospinal fluid (aCSF).  The coronal section containing the infusion site was drop-
fixed in a 4% paraformaldehyde and 15% picric acid in phosphate buffer saline 
solution (PBS) (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4) over-
night.  Brains were then cryoprotected in a 30% sucrose solution in PBS.  Coronal 
brain sections (40µm) were collected using a cryo-stat.  Serial section around the 
infusion site were mounted on gelatin-coated glass slides and partially dehydrated in 
50% ethanol.  Sections were then stained with cresyl violet acetate (Sigma-Aldrich, St.  
Louis, MO) and completely dehydrated in 100% EtOH followed by 3 xylene 
incubations.  Lastly, sections were cover slipped in Permount (Fisher Scientific, 
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Pittsburgh, PA) and let dried over-night.  Images were taken using a Zeiss Axiovert 
S100 microscope and a MicroFire camera (Optronics, Goleta, CA).   
 
BEHAVIORAL TASKS 
 
All behavioral experiments were performed by an experimenter who was kept 
blind to the treatment schedule. 
 
Beam balance task 
 
To assess vestibulomotor and motor functions of Tsc2+/- sham and injured mice 
the beam balance task was performed (4, 202).  On the day after injury, animals were 
given 3 trials of 1 min each on the beam.  Animals were placed at the farthest end of a 
metal beam (0.5 cm wide) and time balancing was recorded.  If 60 seconds passed 
without the mouse falling, the trial was terminated.  At the end of each day, data from 
each animal was averaged and group averages compared.  When all groups 
performed similar to sham controls, testing was ended.   
 
Foot fault task 
 
A second task used to assess vestibulomotor and motor functions of Tsc2+/- 
sham and injured mice was the foot fault task (4, 202).  For this task, a mouse is 
placed on a wire grid with an opening size 1 X 1 cm, and left to walk until the 
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experimenter counted 50 steps.  Foot faults were recorded when any of the front paws 
passed below the plane of observation through a gap in the grid.  Each animal was 
given three trials per day until all groups performed as well as sham controls.   
 
Abbreviated version of the Morris Water Maze (MWM) 
 
Cannulated animals were trained in an abbreviated form of the hidden platform 
version of the Morris water maze task (61, 135, 170).  Animals were trained to criterion 
(three consecutive trials with a platform latency of <10 s).  Each trial started by placing 
the animal in one of four randomly chosen locations, facing the wall of the tank.  
Animals were allowed to search for the platform for 60 s.  If an animal failed to find the 
platform, it was placed there by the experimenter.  Animals were allowed to remain on 
the platform for a period of 30 s before being returned to a warming cage between 
trials.  The inter-trial interval was 4 minutes.  Once criterion was reached, animals 
were immediately infused bilaterally with the corresponding amino acid solution or 
vehicle.  At 48 h after training the animals were tested for memory retention by a probe 
trial in which the hidden platform was removed from the maze and the animals were 
allowed to search for a period of 60 s.  Animals were monitored by a video camera 
linked to tracking software (Ethovision, Noldus).  Data collected during the probe trial 
was divided into respective treatment groups and analyzed for latency to reach the 
platform location, number of times the area of the platform was crossed, swim velocity 
and latency, dwell time and number of crossings to concentric rings of decreasing 
diameter around the platform area.  After the probe trial was complete, the platform 
was placed back into the swimming tank with a visual flag on top.  Animals were given 
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3 trials in which they were allowed to find the marked platform placed in different 
places each trial.   
 
Fear context discrimination 
 
Fear context discrimination was done by pre-exposing animals for 10 min to two 
contexts without shock.  These contexts shared certain features (background noise, 
horizontal grid floor, animal handling to and from the room) but differed in others 
(differently spaced grids, distal cues, floor color, space shape and scent).  Animals 
were given 2 trials a day, one in each of the two chambers.  Half of the animals from 
each group were trained in the morning in the shock chamber were they stayed for 3 
min and a 2 s, 0.75 mA shock given at 148 s.  Then, in the afternoon, they were 
placed in the safe chamber for 3 min and no shock was given.  The complement half 
of each experimental group experienced the same treatment but experienced the 
shock chamber in the afternoon instead.  The following day discrimination between the 
two contexts was assessed by monitoring freezing behavior, in 2 sec intervals for 3 
min, in each chamber.  Contextual discrimination was tested daily; data was compiled 
and analyzed to determine if contextual discrimination was learned.  If learning did not 
happen, then training continued for an extra day until discrimination was achieved 
(47). 
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Delayed fear conditioning 
 
Animals were placed in the training chamber and were allowed to explore for 
120 s.  Then a 30 s tone was presented and during the last two seconds, the animals 
were given a 0.8 mA foot shock through the grid floor (US).  Animals were given three 
successive training trials followed by a one-minute rest period.  Animals were then 
returned to their home cages until retention testing.  Memory for the context, the tone 
and a novel but similar context was independently tested 48 hours later by measuring 
percent freezing.  Freezing was defined as the complete lack of movement except that 
required for breathing.  To test for contextual memory, animals were placed back in 
the training chamber for 3 minutes and freezing behavior was measured at 3-second 
intervals.  To test for fear generalization, animals were placed in a novel context that 
shared certain features with the training context (horizontal grid floor, background 
noise, animal handling to and from the room) while differing in others (differently 
spaced grids, scent, distal cues, floor shape and color) for 3 minutes and freezing 
behavior was measured at 3-second intervals.  To test for hippocampal-independent 
tone memory, animals were placed in a completely different and novel context (plastic 
floor and walls, different lighting and patterns on the walls) and freezing behavior was 
tested for 3 minutes during which the tone was being played.  Freezing behavior was 
monitored and recorded both before and during training (47, 153, 162, 200). 
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WESTERN BLOTS 
 
Antibodies 
The following primary antibodies were purchased from Cell Signaling 
Technology (CST) (Danvers, MA) and dilutions used as follow:  
 Phosphorylated S6 (Serine 240/244) CST Cat.  #5364, 1:2000 
 Total S6 CST Cat.  #2217, 1:2000 
 Phosphorylated S6 Kinase (Threonine 389) CST Cat.  #9205, 1:1000 
 Total S6 Kinase CST Cat.  #9202, 1:1000 
 Phosphorylated Tuberin (Threonine 1462) CST Cat.  #3611, 1:1000 
 Total Tuberin CST Cat.  #3612, 1:1000 
 Phosphorylated ULK1 (Serine 757) CST Cat.  #6888, 1:1000 
 Total ULK11 CST Cat.  #8054, 1:1000 
 Phosphorylated AMPK (Threonine 172) CST Cat.  #2531 1:500 
 Phosphorylated p44/42 MAPK (Erk1/2) (Threonine 202 / Tyrosine 204) 
CST Cat.  #9101, 1:1000 
The following primary antibodies were purchased from Sigma-Aldrich (St.  
Louis, MO) (SIG) and dilutions used as follow: 
 Total Beclin-1 SIG Cat.  #B6186, 1:1000 
 Total β-actin SIG Cat.  #A2228, 1:100000 
To determine how many µg of tissue sample to load for each antibody to fall 
within its linear range of detection, an initial western blot was run with increasing 
amounts of protein, and each antibody tested at the concentrations indicated by the 
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manufacturer.  When necessary, antibody concentrations were adjusted to allow for 
the proper amount of sample to be loaded into wells.   
Alkaline-phosphatase conjugated goat anti-rabbit IgG (AP1000) and alkaline-
phosphatase conjugated goat anti-mouse IgG (AP2000) secondary antibodies were 
purchased from Vector Laboratories (Burlingame, CA).  These antibodies were used at 
a 1:20000 dilution. 
 
Sample preparation 
 
Animals were infused with an amino acid solution into one hippocampus and an 
equal volume of vehicle into the contralateral hippocampus of the same animal.  At the 
indicated time points after infusion, animals were killed and hippocampal punches (2 
mm in diameter) surrounding the infusion site were taken while brains were 
submerged in ice-cold artificial CSF containing phosphatase inhibitors (2 mM NaF, 2 
mM Na2MoO4, and 1 mM Na3VO4).  Tissues were disrupted by 2 second, 20% 
amplitude sonication pulses (Vibra Cell, Ultrasonic processor 130 watt, 20 Khz) 
(Sonics, Newtown, CT) in buffer (10 mM Tris, pH 7.4, 1 mM EGTA, 1 mM EDTA, 0.5 
DTT, 0.1 µM okadaic acid and 1 mM Na3VO4, 1 mM PMSF and 10 µg/ml leupeptin).  
After NuPAGE® LDS sample buffer was added (Invitrogen® by Life TechnologiesTM) 
was added, the protein concentration was determined by NanoOrange Protein 
Quantification Assay (Invitrogen, Carlsbad, CA) using bovine serum albumin (BSA) as 
the standard.   
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Western blot 
 
Samples were boiled in NuPAGE® LDS sample buffer and resolved on 
NuPAGE® Bis-Tris mini gels (Novex® by Life TechnologiesTM).  Proteins were then 
transferred to Immobilon-P (Millipore, Bedfore, MA) membranes and blocked for 30 
min in 5% BSA in TBST.  Primary antibodies were diluted in 2% BSA in TBST as 
indicated in section 2.5.1 and incubated overnight at 4ºC.  Membranes were then 
washed 5 times in TBST and incubated at room temperature with alkaline 
phosphatase-conjugated secondary antibodies at concentrations indicated in section 
2.5.1 for 1 hour.  Membranes were washed again and immunoreactivity was detected 
using the CDP-Star chemiluminescence system (New England Biolabs, Beverly, MA) 
and visualized on Kodak XAR5 film (Rochester, NY).   
 
Quantification of western blot bands 
 
Luminescent membranes were exposed to film with varying exposure times to 
ensure some blots fell within the linear range. Blots that were too dark were not used 
for analysis. Exposed film were scanned and analyzed using Image processing and 
analyzing in java (ImageJ) (171).  Using the rectangular selection tool, samples were 
selected horizontally, then vertically (same rectangle size for each sample).  The 
ImageJ program measured arbitrary units for each sample and plotted the results.  
The area under each curve was calculated and both horizontal and vertical measures 
averaged.  When samples were selected, 1 cm to each side (horizontal measure) or 1 
cm above and below (vertical measure) each band was included and used to remove 
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background optical density produced by the film itself.  All antibodies tested were 
normalized against β-actin.  Western blot data were compiled from at least 3 
independent animals or cell culture experiments and samples were run at least twice 
to confirm results. 
 
IMMUNOHISTOCHEMISTRY 
 
Antibodies 
The following primary antibodies were diluted and used as follow:  
 Phosphorylated S6 (Serine 240/244) CST Cat.  #5364, 1:2000 
 Anti NeuN antibody was purchased from Millipore (Billerica, MA) (Cat.  
#MAB377, 1:1000).   
 Alexa Fluor® 568 Goat Anti-Rabbit IgG (Cat.  #A11011, 1:500) was 
purchased from Invitrogen® by Life TechnologiesTM (Grand Island, NY). 
 Alexa Fluor® 488 Goat Anti-Mouse IgG (Invitrogen® by Life 
TechnologiesTM  Cat.  #A11001, 1:500)  
 
Preparation of tissue sections 
 
Tsc2CKO mice at 5 weeks of age were given 2 daily doses of either 3 g/kg 
glutamine or saline via gavage for 2 weeks.  1 h after the last dose, animals were 
decapitated, and brains immediately removed.  Samples from untreated age-matched 
control littermates were also collected.  Brains were cut in coronal sections of 2 mm 
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while being bathed in ice-cold artificial CSF containing phosphatase inhibitors (2 mM 
NaF, 2 mM Na2MoO4, and 1 mM Na3VO4).  Coronal sections were then drop-fixed in a 
4% paraformaldehyde and 15% picric acid in phosphate buffer saline solution (PBS) 
(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4) over-night.  Brains were 
then cryoprotected in a 30% sucrose solution in PBS.  Coronal brain sections (40 µm) 
were collected using a cryo-stat and stored in protective solution (3.4 M C3H8O3, 5.4 M 
C2H6O2, 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4). 
 
Immunohistochemistry 
 
Brain sections were washed 3 times in PBS solution and then incubated with 
primary antibodies (pS6 and NeuN) overnight at 4ºC in a 0.25% Triton X-100 PBS 
solution (PBST) with 2% BSA and 2.5% normal goat serum.  Brain sections were then 
extensively washed in PBST and incubated for 1 h in species-specific secondary 
antibodies conjugated to Alexa-fluors.  Finally, sections were mounted on glass slides 
and cover slipped using FluoromountG (SouthernBiotech, Birmingham, AL).   
 
Immunofluorescence quantification 
 
Images of immunofluorescence were taken using a Zeiss Axiovert S100 
microscope and a MicroFire camera (Optronics, Goleta, CA).  The parameters used 
for image capturing were determined using control littermate samples to minimize 
background and optimize the signal.  These parameters were kept constant across all 
groups.  Three non-overlapping regions in the dentate gyrus of the hippocampus and 
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two sections from each animal (n=5/group) were used for quantification.  Fluorescence 
intensities were measured using Photoshop software (Adobe, San Jose, CA).  
Luminosity was measured in CA1, CA3 and 3 areas of the dentate gyrus using a 
rectangular selection tool with equal size for every sample.  Relative fluorescence 
intensity units (FIU) were averaged for each section then 2 sections averaged for each 
animal. 
 
STATISTICS 
 
In all experiments, data collected from the same animal with one or more 
factors, was subjected to repeated measures (RM) ANOVA.  Data comparing only one 
factor between groups, such as probe trial data analysis and western blot data, were 
subjected to a two-tailed Student’s t-test for unpaired (behavioral data) or paired 
variables (Western blot data and contextual discrimination data).  Data comparing 
more than 2 groups were subjected to One-way ANOVA.  The analysis of survival was 
performed using the Kaplan–Meier method.  Comparisons between average survival 
times were carried out using the log-rank test.  Data were considered significant at 
p<0.05. 
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CHAPTER 3 
Over-activation of mTORC1 exacerbates 
cognitive impairment after a mild closed head injury 
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INTRODUCTION 
 
Mild traumatic brain injury (mTBI), caused by a kinetic blow to the head, 
accounts for 75% of the 1.7 million TBIs that occur each year (2).  People who have 
suffered more than one mTBI (contact sports athletes and brain injured soldiers) are 
more likely to develop early onset Alzheimer’s disease, chronic traumatic 
encephalopathy and dementias than the uninjured.  This link, between early onset 
neurodegenerative disorders and mTBI, has recently created great interest in this field 
of research (32, 35, 144).  Early symptoms reported include headaches, unsteadiness, 
vomiting, sleeping problems, impaired memory, attention deficits and inability problem 
solving (117, 131, 155).  These symptoms commonly last between days and weeks 
post-injury and most mTBI patients often recover completely. 
Despite the fact that many mTBI patients experience complete recovery, there 
can be long-lasting consequences for some patients both at the functional and 
structural levels.  At the functional level, persistent cognitive impairments and risk for 
the severe consequences of a second injury (second impact syndrome), may happen 
(8, 10, 107).  Evidence suggests that a history of mTBI can cause long-term structural 
changes in the frontal, parietal and temporal brain cortices as well as decreased 
hippocampal volume and reduced neuronal activity (132, 189).  Whether these 
changes contribute to the chronic nature of the neurobehavioral dysfunctions seen in 
mTBI patients or not is still unclear.  Secondary injury events caused by trauma, like 
delayed metabolic and molecular disruptions, may be responsible for the increased in 
brain vulnerability.  Many studies have focused their research on these secondary 
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injury mechanisms because their late start and evolution over hours to months present 
a potential window for treatment (121).   
One example of a secondary mechanism which may be a potential therapeutic 
target is autophagy, the main mechanism for bulk degradation of dysfunctional 
organelles.  This process increases after injury and remains elevated for days (24, 
110, 118, 209).  Immediately after injury, autophagy may have beneficial effects 
including clearing up cellular debris and working in concert with apoptotic processes to 
discard dysfunctional cells (209).  However, chronic elevation of these processes 
could be responsible for excessive loss of neurons in surrounding and distant regions 
from the injury site.  Indeed, several studies have demonstrated that autophagy 
inhibition is correlated with decreased cellular damage and improved behavioral and 
cognitive outcome after TBI (125, 199).  An opposite approach to treat TBI secondary 
injury has been to increase neuronal repair and plasticity.  For example, vascular 
endothelial growth factor administration after TBI promotes behavioral recovery 
possibly due to its role in activation of neurogenesis and angiogenesis (114, 185, 204).  
Application of neurotrophic factors has also been associated with improved outcome 
correlated with increased neurite outgrowth, synaptogenesis and neuronal survival 
(172).  Intriguingly, autophagy and neuroplasticity are regulated by a common 
signaling pathway: the mechanistic Target of Rapamycin Complex 1 (mTORC1) 
pathway. 
MTORC1 acts as a cellular sensor integrating growth factors, mitogens, 
hormones, and ATP availability to regulate cell growth.  As there are many injury-
related alterations in growth factor and cellular energy levels following injury, mTORC1 
is a pathway of theoretical interest to the injury literature.  Most upstream modulators 
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of mTORC1 communicate through the tuberous sclerosis complex (TSC1/2), which 
contains TSC2, a GTPase activating protein for Ras homologue enriched in brain 
(Rheb).  When TSC2 is active, it inhibits Rheb and its subsequent stimulation of 
mTORC1 activity (36, 37, 37, 53, 81, 184, 208).  Thus, abnormal inhibition of TSC—as 
occurs when Tsc2 is mutated—causes overactivation of mTORC1 (28, 71).  Active 
mTORC1 phosphorylates and activates S6K and 4E-BP1 to promote mRNA 
translation initiation (68, 126).  Consequently, deficient neuronal plasticity events after 
injury (like impaired long-term potentiation and decreased synaptic density), may be 
returned to normal by increasing mTORC1 activity (26).  Furthermore, active mTORC1 
also phosphorylates ULK1 to inhibit autophagy initiation.  In this case, increasing 
mTORC1 would target autophagy which could be beneficial or detrimental for TBI 
outcome depending on duration of activation (52, 73, 93, 176). 
There has been investigation of mTORC1 activation following injury, but no 
conclusive results as to the activation state or its impact upon outcome.  One issue 
with the current literature is that not enough emphasis has been placed on 
investigating mTORC1 activity in a temporal manner.  It has been shown that 
mTORC1 activity is increased from 30 min to 24 hours after TBI (20).  To test whether 
this acute increase in mTORC1 activity is beneficial or detrimental to TBI outcome, 
Erlich et al.  treated injured mice with Rapamycin, an mTORC1 specific inhibitor, 4 hrs 
after injury.  Surprisingly, they found that treated mice had improved neuro-motor 
functions compared to the vehicle group (44).  However, other work has shown that 
rapamycin treatment alone was unable to improve cognitive outcome unless co-
infused with an Akt inhibitor (147).  Contrary to these findings, chronic elevated levels 
of mTORC1 have been shown to be required for axonal regeneration of injured 
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peripheral nerves (3).  Supporting the view that high mTORC1 activity improves TBI 
outcome, increased synapse and axonal recovery growth after TBI was observed 
following 14 days of treatment with the drug Simvastatin, which increased 
PI3K/Akt/mTORC1 signaling (204).  These results suggest that this pathway could be 
a potential therapeutic option for TBI patients but it remains unclear whether inhibition 
or activation of mTORC1 would improve outcome.   
My hypothesis is that if elevated mTORC1 activity is detrimental for TBI 
outcome, then TSC2 heterozygous knock-out mice (Tsc2+/KO) will show poor outcome 
after brain injury compared to control littermates (Tsc2+/+).  To test this hypothesis I 
completed the following specific aims: 
I. Genetic rodent models with inactivation of Tsc2 show variable learning and 
memory deficits (41, 195).  It is not clear whether a graded inactivation of 
TSC1/2 (caused by haploinsuficiency) or subsequent loss of heterozygosity 
is the mechanism behind cognitive deficits seen in Tuberous Sclerosis 
Complex (TSC) patients (28).  I therefore sought to assess the brain 
expression levels of Tsc2 and downstream target of mTORC1 (phospho-S6) 
and characterize learning and memory performance in our Tsc2+/KO mice. 
II. MTORC1 activity increases following brain injury and its inhibition with 
rapamycin improves outcome (20, 44).  Therefore, I anticipated that Tsc2+/KO 
mice, which have increased mTORC1 activity, would have an exacerbated 
and acute impairment of memory and increased mTORC1 activity after a 
mild closed head injury (mCHI).  I investigated this possibility by delivering a 
mild CHI to Tsc2+/KO and Tsc2+/+ mice and testing phospho-S6 levels 30 
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minutes after injury and learning and memory performance one week 
following the insult.   
III. It is still unclear if mTORC1 activity could be beneficial or detrimental in the 
chronic phases after brain injury.  Some studies suggest that mTORC1 role 
in cellular growth and plasticity would be beneficial, while others argue 
against it (38, 96).  To test whether overactivation of mTORC1 improves TBI 
outcome, I assessed phospho-S6 levels seven weeks after mCHI and tested 
learning and memory performance five weeks following injury in Tsc2+/KO 
mice.   
 
MTORC1 ACTIVITY IS ELEVATED IN TSC2+/KO MICE BUT LEARNING AND 
MEMORY PERFORMANCE IS COMPARABLE TO TSC2+/+ MICE 
 
mTORC1 activity is elevated in Tsc2+/KO mice 
 
Tsc2+/KO mice were generated in Dr. Gambello’s laboratory and have been 
previously described. These animals show decreased Tsc2 protein levels and elevated 
phospho-S6 (71).  To reproduce these results, I used cortex and hippocampal tissue 
from Tsc2+/KO and Tsc2+/+ and compared protein levels of tuberin, phospho-S6 and 
total S6 by western blot.  As expected, a mild decrease in tuberin levels of Tsc2+/KO 
brains was observed (Fig 3.1A).  Tuberin binds to hamartin to form the TSC complex 
which acts as a negative regulator of mTORC1 activity.  The mutation is expected to 
decrease the amount of active TSC complex, leading to decreased inhibition of 
mTORC1 and increased phosphorylation of its downstream targets.  My results show 
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that levels of phospho-S6 are significantly higher in Tsc2+/KO than Tsc2+/+ mice while 
its total levels remain unchanged (Fig 3.1B and C). 
 
Figure 3.1: Tsc2 is reduced while pS6 is elevated in Tsc2+/KO mice.  Tsc2+/KO mice 
(n=5) and control littermates (n=5) of 2 month of age were decapitated and brain 
samples collected for western blot analysis.  A) Tsc2+/KO mice have significantly lower 
levels of tuberin than control littermates (Tsc2+/+) in cortex (left, p=0.037) and 
hippocampus (right, p=0.019).  B) Tsc2+/KO mice have significantly higher levels of 
phosphorylated-S6 than Tsc2+/+ in cortex (left, p=0.039) and hippocampus (right, 
p=0.028).  C) There is no significant difference in total levels of S6 between the two 
groups in cortex (left, p=0.5) and hippocampus (right, p=0.8).  Data are represented as 
the mean ± s.e.m; statistical analysis done by 2-tailed, unpaired student’s t-test; 
*p≤0.05. 
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Tsc2+/KO mice have no motor or cognitive deficits 
 
Brain injury can cause motor and vestibulomotor deficits which can be detected 
using the foot fault and beam balance tasks, respectively.  To ensure that any effects 
following TBI were specific to the injury and not due to a baseline difference in motor 
and cognitive performance, I tested animals in the beam balance and foot fault tasks.  
When Tsc2+/KO mice are compared to Tsc2+/+ control litter mates, there is no difference 
in time balancing on the metal beam or foot faults while walking on a metal grid (Fig 
3.2). 
Upon confirmation that there were no pre-existing deficits in motor performance, 
I then trained and tested Tsc+/KO and Tsc2+/+ mice in an abbreviated version of the 
Morris water maze to investigate their abilities to form hippocampal-dependent 
memories.  Animals were given 10 consecutive trials (4 min inter-trail-interval) to find a  
hidden platform in the water maze.  There was no difference in learning between 
Tsc2+/KO and Tsc2+/+ groups (Fig 3.3A).  When tested for long-term memory 24 h after 
training, there was no significant difference in latency to the original platform location 
or number of crosses through the platform area (Fig 3.3A and B).  This suggests that 
Tsc2+/KO mice are able to form normal long-term spatial memories. 
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Figure 3.2: Motor skills are not affected in Tsc2+/KO mice.  Tsc2+/KO mice (n=10) and 
Tsc2+/+ (n=9) of 2 to 4 month of age were tested for motor ability.  A) There was no 
difference between the groups in the paw placement task, p=0.8.  B) There was no 
difference between the groups in the beam balance task, p=0.2.  Data represent 
means ± s.e.m. 
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Figure 3.3: Tsc2+/KO mice have no deficit in the Morris Water Maze task.  Tsc2+/KO 
mice (n=10) and Tsc2+/+ (n=9) were trained in a 1-day Morris Water Maze protocol.  A) 
There was no difference during learning between the groups, (2-way repeated 
measures of ANOVA with group and training trial as between subject factors: 
F(4,68)=0.393, p=0.8).  There was no significant difference between the groups in a 
probe trial given 24 hrs later, latency is shown (2- tailed, unpaired student’s t-test; 
p=0.5).  B) There was no difference between the groups in the number of crossings 
during the probe trial (2- tailed, unpaired student’s t-test; p=0.25).  C) There was no 
difference between the groups in the latency to a visual platform (2- tailed, unpaired 
student’s t-test; p=0.8).  D) There was no difference between the groups in swim 
velocity during the probe trial (2- tailed, unpaired student’s t-test; p=0.3).  Data 
represent means ± s.e.m. 
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To further confirm that Tsc2+/KO mice have no deficits making hippocampal-
dependent memories, mice were trained in a fear context discrimination paradigm.  
Animals were initially pre-exposed to the shock chamber and to a modified chamber 
resembling the shock cage but differing in wall cues, scent, floor grid spacing and 
shape (safe cage).  Half of the animals from each group were given a morning trial in 
the shock cage (3 min, 2 s 0.75 mA shock given at 148 s) and an afternoon trial in the 
safe cage (3 min, no shock).  The other half of the animals received the same training 
but in reverse order.  To assess fear memory retention, animals were placed in each 
cage 24 h later and freezing behavior monitored.  My results show that both groups 
froze for a significantly longer period of time in the shock cage than in the safe cage 
(Fig 3.4).  This result indicates that Tsc2+/KO mice were able to remember the context-
shock relationship as well as control litter mates, and supports the idea that Tsc2+/KO 
mice present no pre-existing hippocampal-dependent memory deficits.   
 
 
 
 
Figure 3.4: Tsc2+/KO mice have no deficit in a fear context discrimination task.  
Tsc2+/KO mice (n=10) and Tsc2+/+ (n=9) were trained in a context discrimination task 
for one day and tested for memory 24 hrs later, % freezing is shown for baseline 
conditions.  A) Control mice froze significantly less time in the safe cage than in the 
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shock case, indicating they could discriminate between them, p=0.024.  B) Tsc2+/KO 
mice froze significantly less time in the safe cage than in the shock case, indicating 
they could also discriminate between the two cages, p=0.004.  Data represent means 
± s.e.m., statistical analysis done by 2-tailed, unpaired student’s t-test, *p<0.05, 
**p<0.01. 
 
MTORC1 ACTIVITY IS FURTHER ELEVATED IN TSC2+/KO MICE AFTER CLOSED 
HEAD INJURY 
 
As shown in the previous section, Tsc2+/KO mice have constitutively elevated 
mTORC1 activity, but have no learning and memory deficits in the Morris water maze 
or context discrimination tasks.   
To test if a brain injury differentially activates mTORC1 in Tsc2+/KO and Tsc2+/+ 
littermate mice, a mild closed head injury (CHI) was delivered to animals of both 
groups.  Figure 3.5 shows that both groups had comparable apnea time, response 
time to a tail pinch and righting responses.  This indicates that the severity of the 
concussion was comparable in both groups.  Brains were dissected 30 min after injury 
and hippocampus (HIPP) and cortex (CTX) tissue was collected for western blot 
analysis.   
 
 
53 
 
 
 
Figure 3.5: There is no difference in apnea, Tail pinch and Righting response between 
Tsc2+/KO and control mice after closed head injury.  Tsc2+/KO mice (n=5) and control 
littermates (n=6) of 2-4 months of age were injured with a pneumatically driven 
controlled cortical impact device and the following test performed immediately after the 
impact.  A) There was no difference in apnea between the two groups, p=0.7 B) There 
was no difference in tail pinch response between the two groups, p=0.3 C) There was 
no difference in righting response between the two groups, p=0.2.  Data are 
represented as the mean ± SEM; statistical analysis done by 2-tailed, unpaired 
student’s t-test. 
 
To test whether or not mTORC1 activity was differentially upregulated in 
Tsc2+/KO and Tsc2+/+ mice, western blots were performed using phospho-S6, a 
sensitive downstream target of mTORC1.  My results show that phospho-S6 levels did 
not change when injured Tsc2+/+ are compared to sham controls (Fig 3.6A).  However, 
when Tsc2+/KO are injured, higher levels of phospho-S6, but not its total levels, are 
observed when compared to their sham group (Fig 3.6B and C).   
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Figure 3.6: Phosphorylated S6 levels are elevated in Tsc2+/KO mouse brains 30 
minutes after CHI.  Tsc2+/KO mice (n=5) and Tsc2+/+ (n=6) of 2-4 months of age were 
injured with a pneumatically driven controlled cortical impact device and brain tissue 
dissected 30 min after the impact.  A) Top, representative western blots.  Bottom left, 
pS6 levels do not change after CHI in control mice in cortex (p=0.4) and hippocampus 
(p=0.6) when compared to sham control mice (n=6).  Bottom right, total S6 levels do 
not change after CHI in control mice when compared to sham group (CTX p=0.4, HIPP 
p=0.3).  B) Top, representative western blots.  Bottom left, pS6 levels are significantly 
higher than sham control mice (n=6) in Tsc2+/KO mouse cortex (p=0.0009) and 
hippocampus (p=0.0003).  Bottom right, total S6 levels do not change after CHI in 
Tsc2+/KO mice when compared to control sham (CTX p=0.4, HIPP p=0.4).  Data 
represent means ± s.e.m., statistical analysis done by 2-tailed, unpaired student’s t-
test, ***p<0.001. 
 
MTORC1 has been shown to regulate autophagy by phosphorylating, and 
inhibiting ULK1.  To test the possibility that injury-associated increased mTORC1 
activity also affected this target, brain samples were tested by western blot using a 
phospho-ULK1 antibody.  Figure 3.7 shows that injured control Tsc2+/+ mice do not 
show increased phospho-ULK1 levels when compared to sham controls (Fig 3.7A).  
On the other hand, injured Tsc2+/KO mice show elevated phospho-ULK1 levels when 
compared to Tsc2+/KO sham, while its total levels remain unchanged (Fig 3.7B).  This 
result complements the previous finding that mTORC1 activity is elevated in injured 
Tsc2+/KO but not injured Tsc2+/+ and suggest that mTORC1 activation following TBI 
affects both autophagy and protein synthesis.   
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Figure 3.7: Phosphorylated ULK1 levels are elevated in Tsc2+/KO mice 30 minutes 
after CHI.  Tsc2+/KO mice (n=5) and Tsc2+/+ (n=6) of 2-4 months of age were injured 
with a pneumatically driven controlled cortical impact device and brain tissue dissected 
30 min after the impact.  A) Top, representative western blots.  Bottom left, pULK1 
levels do not change after CHI in control mice in cortex (p=0.7) and hippocampus 
(p=0.9) when compared to a sham group (n=6).  Bottom right, total ULK1 levels do not 
change after CHI in control mice when compared to a sham group (CTX p=0.7, HIPP 
p=0.7).  B) Top, representative western blots.  Bottom left, pULK1 levels are 
significantly higher than sham control mice (n=6) in Tsc2+/KO mouse cortex (p=0.01) 
and hippocampus (p=0.038).  Bottom right, total ULK1 levels do not change after CHI 
in Tsc2+/KO mice when compared to control sham (CTX p=0.9, HIPP p=0.6).  Data 
represent means ± s.e.m., statistical analysis done by 2-tailed, unpaired student’s t-
test, *p<0.05. 
 
However, there is also a possibility that Tsc2+/+ mice do not show elevated 
levels of mTORC1 activity because the concussion was too mild to create any deficits.  
Therefore, the levels of Beclin-1 were also tested in these samples.  Beclin-1 is a 
protein involved in autophagy activation and its total levels have been shown to be 
elevated after brain injury.  My results show a significant increase in the total levels of 
Beclin-1 in both injured groups (Fig 3.8A and B).  These results support the idea that 
brain injury differentially affects mTORC1 activity in Tsc2+/KO mice than control 
littermates.  In summary, upon a mild closed head injury, a noticeable increase in the 
phosphorylation levels of mTORC1 downstream target S6 is only observed when Tsc2 
levels are decreased (haploinsuficiency).  Furthermore, phosphorylation of a second 
mTORC1 target, ULK1, necessary to regulate autophagy, is also increased only in 
Tsc2+/KO injured animals.  These results suggest that abnormal mTORC1 activity due 
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to partial lack of Tsc2 regulation decreases the internal threshold to elevate mTORC1 
activity after injury.   
 
 
 
Figure 3.8: Beclin-1 levels are elevated 30 minutes after CHI in the cortex of Tsc2+/KO 
and Tsc2+/+ mice.  Tsc2+/KO mice (n=5) and control littermates (n=6) of 2-4 months of 
age were injured with a pneumatically driven controlled cortical impact device and 
brain tissue dissected 30 min after the impact.  A) Representative western blots.  B) 
Beclin-1 levels are elevated 30 min after CHI in both Tsc2+/+ (p=0.004) and TSC2+/KO 
mice (p=0.0002) when compared to a respective sham group.  Data represent means 
± s.e.m., statistical analysis done by 2-tailed, unpaired student’s t-test, **p<0.01, 
***p<0.001. 
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COGNITIVE IMPAIRMENT IS EXACERBATED IN TSC2+/KO MICE AFTER CLOSED 
HEAD INJURY 
 
I have shown in the previous section that a mild closed head injury increases 
levels of phosphorylated S6 and ULK1, two downstream targets of mTORC1.  To test 
whether or not acute activation of mTORC1 signaling is detrimental to cognitive 
outcome after TBI, Tsc2+/KO and control littermates were injured and their memory 
forming ability tested in the Morris water maze and context discrimination tasks.  
Figure 3.9 shows the timeline of experiments performed following delivery of a mild 
closed head injury. 
 
 
Figure 3.9: Time line of experiments.  Tsc2+/KO mice (n=9) and Tsc2+/+ (n=10) of 2-4 
months of age received a closed head injury with a pneumatically driven controlled 
cortical impact device.  Immediately after the impact, acute neurological tests (apnea, 
tail pinch response and righting response) were performed.  On the first day after the 
injury, animals were tested on 2 motor skills tasks: paw placement and beam balance.  
During the first week after CHI, animals were trained and tested in a 1-day protocol of 
the Morris water maze.  During the second week after CHI, animals were trained and 
tested in a fear context discrimination task. 
60 
 
 Immediately after the injury, animals were tested for apnea, tail pinch and 
righting response times.  There was no difference in any of these tests between the 
two injured groups indicating that severity of the injury was equal in both groups (Fig 
3.10A, B and C).  Figure 3.10D shows that both injured groups performed the foot fault 
tasks in a comparable manner to sham animals, suggesting no deficits in this test.  
Figure 3.10E shows that both injured groups were similarly impaired in the foot fault 
tasks and took them the same time to recover to sham standards.  This again 
suggests that the injury level was similar in both groups and affected their ability to 
recover in a similar manner.   
One week after injury, animals were trained to find a hidden platform in the 
Morris water maze.  Mice were given 10 consecutive trials (4 min ITI) and returned to 
their home cages.  Figure 3.11A shows that both injured groups learned the task.  To 
test for memory of the platform location, animals were given a probe test 24 h after the 
last training trial.  Figure 3.11A and B show that Tsc2+/KO mice spent more time 
searching without finding the platform location (Tsc2+/+ 29.1 ± 8.1 latency; Tsc2+/KO 
50.31 ± 5.2, p=0.046) and crossed the platform area less times than Tsc2+/+ mice 
(Tsc2+/+ 1.4 ± 0.4 crossings; Tsc2+/KO 0.33 ± 0.1, p=0.039).  These results suggest that 
long-term memory of the platform location was impaired in Tsc2+/KO injured mice when 
compared to injured control littermates.  The results cannot be attributed to visual 
acuity problems or swimming deficits since there was no difference between the 
groups in latency to find a visible platform (Fig 3.11C) or swim velocity (Fig 3.11D).   
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Figure 3.10: There is no difference between Tsc2+/KO mice and control littermates in 
acute neurological tests and motor skills after a mCHI.  A sham group (n=8) is shown 
for reference on each panel.  A) There was no significant difference in apnea between 
the two groups, 2-tailed, unpaired student’s t-test p=0.8.  B) There was no significant 
difference in tail pinch response between the two groups, 2-tailed, unpaired student’s 
t-test p=0.2.  C) There was no significant difference in righting response between the 
two groups, 2-tailed, unpaired student’s t-test p=0.4.  D) There was no significant 
difference in the paw placement task (2-way repeated measures of ANOVA with group 
and training day as between subject factors: F(2,32)=1.044, p=0.36.  E) There was no 
significant difference in the beam balance task between the groups, (2-way repeated 
measures of ANOVA with group and training day as between subject factors: 
F(2,34)=0.329, p=0.7).  Data are represented as the mean ± s.e.m.  
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Figure 3.11: Tsc2+/KO mice exhibit impaired memory in the MWM task after a mCHI.  A 
sham group (n=8) is shown for reference on each panel.  A) There was no difference 
during learning between the groups, (2-way repeated measures of ANOVA with group 
and training trial as between subject factors: F(4,68)=1.021, p=0.4).  A significant 
difference in a probe trial given 24 hrs later between the groups was found, latency is 
shown (2- tailed, unpaired student’s t-test; p=0.046).  B) There was also a significant 
difference in the number of crossings during the probe trial (2- tailed, unpaired 
student’s t-test; p=0.039).  C) There was no difference between the groups in the 
latency to a visual platform (2- tailed, unpaired student’s t-test; p=0.9).  D) There was 
no difference between the groups in swim velocity during the probe trial (2- tailed, 
unpaired student’s t-test; p=0.9).  Data represent means ± s.e.m., *p<0.05. 
 
 To confirm that injured Tsc2+/KO mice have poorer cognitive recovery than 
Tsc2+/+ mice, animals were trained in a fear context discrimination task as described in 
section 3.2.  My results show that, as expected, sham animals are able to learn the 
task after only one training trial (Fig 3.12A).  Injured Tsc2+/+ mice learn the task a day 
slower than sham animals (Fig 3.12B) and injured Tsc2+/KO mice required 3 trials to 
learn the task (Fig 3.12C).  These results suggest that Tsc2+/KO mice need an extra 
amount of training to distinguish between the shock and safe cages.   
In summary, increased mTORC1 activity, due to a Tsc2 mutation, impairs TBI 
outcome.  Together, the results of this and the previous section support the idea that 
mTORC1 overactivation after brain injury is indeed detrimental for recovery. 
 
 
64 
 
 
65 
 
(On previous page) 
 
Figure 3.12: Tsc2+/KO mice exhibit impaired memory in a context discrimination task 
after a mCHI.  A) Control SHAM animals learn the task after one training trial and 
progressively get better at distinguishing between the two cages, (2-way repeated 
measures ANOVA with cage and trial number day as between subject factors: group 
main effect F(1,7)=34.515, p<0.001).  B) Control mCHI mice acquire the task in two 
trials, (2-way repeated measures ANOVA with cage and trial number as between 
subject factors: F(2,16)=4.918, p=0.022).  C) Tsc2+/KO mCHI mice three trials to learn 
the task, (2-way repeated measures ANOVA with cage and trial number as between 
subject factors: F(2,18)=6.139, p=0.009.  Data represent means ± s.e.m., *p<0.05, 
**p<0.01, ***p<0.001, †p<0.05, ‡p<0.001. 
 
TSC2+/KO MICE RECOVER BY 5 WEEKS AFTER A MILD CLOSED HEAD INJURY 
 
Brain injury causes acute as well as late repercussions.  I have shown in the 
previous sections of this chapter that mTORC1 activity increases in Tsc2+/KO but not 
control littermates.  This increase is correlated with a deficit in hippocampal-dependent 
memory during the first few weeks after injury.  However, mTORC1 is also known to 
positively regulate brain plasticity and its increased activation, in TSC2+/KO mice, could 
be beneficial for brain repair and recovery at later stages following injury.  My 
hypothesis is that if increased mTORC1 activity positively regulates neuronal growth 
and plasticity, then injured Tsc2+/KO mice will show better outcome at later stages 
following CHI.  To test this hypothesis a mild closed head injury was delivered to 
Tsc2+/KO and Tsc2+/+ mice and learning and memory tested 5 weeks after injury (Fig 
3.13).  Acute neurological tests and motor skills were not significantly different 
between the two groups (Fig 3.14).   
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Figure 3.13: Time line of experiments.  Tsc2+/KO mice (n=10) and control littermates 
(n=10) of 2-4 months of age were injured with a pneumatically driven controlled 
cortical impact device.  Immediately after the impact, acute neurological tests (apnea, 
tail pinch response and righting response) were performed.  On the first day after the 
injury animals were tested on 2 motor skills tasks: paw placement and beam balance.  
There was a break of 4 weeks and then during the fifth week after mCHI, animals were 
trained and tested in a 1-day protocol of the Morris water maze.  During the sixth week 
after mCHI animals were trained and tested in a fear context discrimination task.  At 
the end of these behavioral tests, animals were killed and brains dissected for western 
blot analysis. 
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Figure 3.14: There is no substantial difference between Tsc2+/KO mice and control 
littermates in acute neurological tests and motor skills after a mCHI.  A sham group 
(n=8) is shown for reference on each panel.  A) There was no significant difference in 
apnea between the two groups, 2-tailed, unpaired student’s t-test p=0.35.  B) There 
was no significant difference in tail pinch response between the two groups, 2-tailed, 
unpaired student’s t-test p=0.3.  C) Tsc2+/KO mice recovered from the righting response 
significantly faster than their control litter mates after a mCHI, 2-tailed, unpaired 
student’s t-test p=0.007.  D) There was no significant difference in the paw placement 
task between the two groups, (2-way repeated measures of ANOVA with group and 
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training day as between subject factors: F(2,36)=1.578, p=0.22).  E) There was no 
significant difference in the beam balance task between the two groups, (2-way 
repeated measures of ANOVA with group and training day as between subject factors: 
F(2,36)=1.253, p=0.3.  Data are represented as the mean ± s.e.m., **p<0.01. 
 
Five weeks after suffering a mCHI, animals were trained in the Morris water 
maze as specified in section 3.4.  When long-term memory was tested 24 h after the 
last trial, there was no difference between injured heterozygous Tsc2+/KO and injured 
Tsc2+/+ mice in latency to find the platform location or number of crossing through the 
platform area (Fig 3.15A and B).  Furthermore, there was no difference between the 
two groups when animals were trained and tested in a fear context discrimination task 
(Fig 3.15C).  The previous section showed that Tsc2+/KO animals had impaired 
hippocampal-dependent long-term memory when tested at subacute times (first 2-3 
weeks after injury), suggesting that over activation of mTORC1 signaling exacerbates 
TBI-associated learning and memory dysfunction.  The results in this section show that 
both groups of injured animals were able to accurately form hippocampus-dependent 
long-term memories when tested in the chronic phase of injury.  This indicates that 
overactivation of mTORC1 does not cause lasting dysfunction.  However, it is not 
possible to say if mTORC1 overactivation is beneficial in the chronic phases after TBI 
due to the fact that both groups recovered at the time tested.   
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Figure 3.15: Tsc2+/KO mice have no impairment in the MWM and context 
discrimination tasks 5 weeks after a mCHI.  A) There was no difference during learning 
between the groups, (2-way repeated measures of ANOVA with group and training 
trial as between subject factors: F(4,72)=0.633, p=0.6).  No significant difference in a 
probe trial given 24 hrs later was found, latency is shown (2- tailed, unpaired student’s 
t-test; p=0.8).  B) There was no significant difference in the number of crossings during 
the probe trial (2- tailed, unpaired student’s t-test; p=0.2).  C) Control SHAM mice 
(left), Control mCHI mice (middle) and Tsc2+/KO CHI mice (right) froze significantly less 
time in the safe cage than in the shock cage, after one day of training, indicating they 
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could discriminate between them, (2- tailed, unpaired student’s t-test; Control SHAM, 
p=0.006; Control CHI, p=0.036; Tsc2+/KO CHI, p=0.0095).  Data represent means ± 
s.e.m., *p<0.05, **p<0.01. 
 
Tsc2+/KO animals showed a complete recovery 4-6 weeks after injury.  This 
result could be due to a drop in mTORC1 activity levels.  To test the possibility that 
mTORC1 activity was reduced to baseline levels 6 weeks after injury, brain samples 
were probed for phospho-S6 and phospho-ULK1 by western blot.  My results show no 
significant difference between injured and sham Tsc2+/KO animals (Fig 3.16A and B) 
suggesting that the cognitive recovery observed could be attributed to mTORC1 
activity return to baseline.    
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Figure 3.16: pS6 and pULK1 levels return to baseline 6 weeks after a mCHI.  Tsc2+/KO 
mice (n=5) of 2-4 months of age were injured with a pneumatically driven controlled 
cortical impact device and brain tissue dissected 6 weeks after the impact and 
compared to a SHAM group (n=4).  A) Top, Representative western blots.  Bottom, 
pS6 levels return to baseline 6 weeks after CHI, cortex (p=0.4) and hippocampus 
(p=0.1) when compared to a sham group.  B) Top, Representative western blots.  
Bottom, pULK1 levels return to baseline 6 weeks after CHI, cortex (p=0.3) and 
hippocampus (p=0.98) when compared to a sham group.  Data represent means ± 
s.e.m., statistical analysis done by 2-tailed, unpaired student’s t-test 
 
SUMMARY AND DISCUSSION 
 
In this chapter, I investigated the effects of elevated mTORC1 activity of 
Tsc2+/KO mice, on mild closed head injury (CHI) outcome.  I used hippocampal-
dependent learning and memory tasks to test cognitive deficits before and after the 
trauma.  My results show that Tsc2+/KO mice have elevated levels of phospho-S6, a 
well-documented indicator of mTORC1 activity.  However, Tsc2+/KO mice do not show 
any learning and memory deficits in the Morris water maze or fear contextual 
discrimination tasks.  After CHI, elevated levels of phospho-S6 and phospho-ULK1 are 
observed only in Tsc2+/KO mice but not control litter mates.  This acute (30 min) 
overactivation of mTORC1, caused by a mild closed head injury, impairs long-term 
memory formation within 2-3 weeks after the insult in Tsc2+/KO.  Interestingly, 6 weeks 
after injury, mTORC1 levels return to baseline and animals recover as well as control 
littermates.  These results could aid in the design of treatments for brain-injured 
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patients that differentially target the mTOR pathway in a temporally specific manner 
following trauma. 
The mTORC1 pathway is involved in synaptic plasticity necessary for memory 
formation.  Targeted inhibition of this pathway impairs memory and its misregulation, in 
diseases like TSC, causes neuropsychological impairments as well.  Among the first 
TSC animal models to be discovered was the Eker rat.  These animals carry a 
spontaneous germ line mutation in the Tsc2 gene, but only mild brain pathologies 
have been observed.  Consequently, these rats have minor behavioral deficits, have 
no impaired hippocampal-dependent learning and memory and do not suffer epileptic 
seizures (43, 195).  In contradiction, a mouse model of TSC, created by mutating Tsc2 
using gene targeting, showed long-term memory deficits for the standard version of 
the Morris water maze and contextual fear discrimination (41, 145).  A different TSC 
mouse model containing a dominant negative allele of Tsc2 only showed mild 
impairments in hippocampal dependent memory tasks (21, 57).  This variability in 
results between rodent models of TSC could be caused by differences in background 
between strains and species (104, 145).  It has also been suggested that brain 
abnormalities in TSC patients develop due to a mutational “two-hit” model.  Scientists 
supporting the “two-hit” model argue that a second mutation in the functional Tsc1 or 
Tsc2 allele, which produces loss of heterozygosity, is the mechanism for brain lesion 
formation.  However, results supporting this view are contradictory with some 
publications demonstrating the existence of mutations in both alleles (in tissue from 
brain lesions only) and others suggesting that second hit mutations are rare 
occurrences (28, 58, 70, 158).  Whether overactivation of mTORC1 pathway is 
sufficient to produce cognitive impairments or they are caused by brain lesions is still 
73 
 
unclear.  My results support the idea that Tsc2+/KO mice have no deficits in 
hippocampal-dependent long-term memory formation even though mTORC1 activity 
levels are elevated when compared to Tsc2+/+ control mice.  However, Tsc2+/KO mice 
provide an interesting model to test the hypothesis that, like a second-hit mutation, a 
brain insult that further increases mTORC1 activity, would impair memory formation.   
Traumatic brain injury (TBI) has been shown to produce acute elevation of 
mTORC1 activity (20) but it is unclear if this finding is beneficial or detrimental to 
outcome.  After a brain injury, metabolic and molecular pathways may change in ways 
that render the brain vulnerable to further injury or accelerate neurodegenerative 
diseases.  The mTORC1 pathway holds a key role integrating cellular signals to 
regulate both macromolecule biosynthesis and autophagy.  Considering that protein 
and lipid synthesis is necessary for the repair of damaged neuronal connections, one 
might argue that increased mTORC1 activity would aid this processes.  On the other 
hand, active mTORC1 inhibits autophagy, also thought to play a role in cellular 
responses to brain injury.  Some studies suggest that inhibition of mTORC1 activity 
improves TBI outcome, while others imply the opposite (44, 120, 147, 148).  To further 
understand the role of mTORC1 in TBI outcome, I delivered a mild closed head injury 
to Tsc2+/KO mice.  Uninjured Tsc2+/KO mice show elevated mTORC1 activity but no 
cognitive impairments.  When injured, Tsc2+/KO mice show further activation of the 
mTORC1 pathway accompanied by memory deficits.  The activation of mTORC1 was 
measured by observing the levels of phospho-S6 (increased protein synthesis) and 
phospho-ULK1 (decreased autophagy).  An increase in both S6 and ULK1 
phosphorylation levels suggests that both processes are affected by mTORC1 
dysregulation.  Yet downstream signaling mechanisms could be interfering with the full 
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activation or inactivation of these pathways.  Therefore, it is still unclear whether active 
protein synthesis or autophagy or both is the mechanism responsible for impaired 
outcome after TBI.  Future studies should be designed to understand the role of each 
individual pathway in TBI outcome as well the cooperative effect they might show 
when misregulated concomitantly.   
Interestingly, after 4-6 weeks, mTORC1 levels return to baseline and 
performance in the Morris water maze and fear context discrimination task are 
comparable to control animals.  This suggests that acute mTORC1 activity can be 
detrimental for memory formation only after crossing an activation threshold.  Whether 
or not overactivation of mTORC1 could be beneficial in the chronic phases of TBI 
remains unclear.  Future experiments delivering moderate to severe injuries would aid 
in this matter.   
My results support the idea that mTORC1 overactivation has an important role 
in TBI cognitive outcome.  However, they do not exclude the possibility that mTORC1 
is interacting with other signaling cascades to produce the observed deficit.  
Apoptosis, cellular stress and inflammatory signals have also been shown to be 
activated in response to brain injury (174).  Consequently, the cognitive impairments I 
observed could be due to mTORC1 interaction with other deregulated signaling 
cascades.  TBI is a multi-system disorder, and as such a multi-target treatment 
approach should be design.  However, the results from this chapter suggest that 
decreasing mTORC1 activity in multiple cell types of the brain could be a potential 
treatment for TBI.  Further research is needed to understand how the interactions 
between different signaling pathways and mTORC1 affect TBI outcome. 
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It is estimated that 75% of all reported TBIs are classified as mild.  Physicians 
use a relatively straightforward definition of mild TBI set by The Centers for Disease 
Control and Prevention, the World Health Organization and the United States Veterans 
affairs/Department of Defense (35).  However, it has been difficult to establish a 
defined criteria regarding mild TBI in experimental animals.  A recent comprehensive 
review, addressing the difficulties modeling mild TBI in the laboratory, suggests that 
loss of consciousness could be a parameter to measure TBI severity (35).  In rodents, 
the duration to recover the righting reflex is considered an analogue to loss of 
consciousness in humans.  This test seems to be a good indicator of injury level and 
the authors suggest that suppression of righting reflex between 5-20 min after injury 
lacking any intracranial abnormalities should be classified as mild.  The experimental 
design related to this chapter held into account the possibility that a moderate to 
severe closed head injury would mask any differences between Tsc2+/KO and Tsc2+/+ 
mice due to a ceiling effect.  My results show that righting reflex suppression never 
extended more than 20 min and preliminary brain immunohistochemistry showed no 
alterations in NeuN (cell loss), Nestin (reactive astrocytes) or Myeloperoxidase 
(neutrophil infiltration) immunoreactivity (Not shown).  Therefore, the severity of the 
injury delivered to Tsc2+/KO mice and control littermates could be categorized as mild.  
An interesting extension of my findings would be to repeat the above experiments but 
administering a moderate to severe level of injury.  Presumably, more severe injuries 
would further increase mTORC1 levels acutely and extend the amount of time 
mTORC1 remains overactive.  In support of the conclusions from my results, I would 
hypothesize that an even greater increase in mTORC1 activity following TBI would 
further impair cognition.  This would be seen as either a more pronounced dysfunction 
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in hippocampal-dependent memory tasks and/or as a prolonged deficit, lasting weeks 
to months.  Prolonged overactive mTORC1 would be expected to reduce autophagy 
and lysosomal biosynthesis, which can be detrimental to long-term recovery.  This 
could further our understanding of the molecular events and their function after TBI 
and its progression.   
In conclusion, my results demonstrate that when mTORC1 pathway is 
compromised, a further insult to the system can lead to noticeable cognitive 
impairments.  This suggests that mTORC1 pathway could be a potential secondary 
mechanism involved in brain vulnerability after TBI.  However, my results show that its 
activity is returned to basal levels at least as early as 6 weeks after mild closed head 
injury.  Further studies examining the effects of severe TBI as well as interactions 
between mTORC1 and other molecular pathways after injury are needed to better 
understand TBI pathology. 
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CHAPTER 4 
Glutamine reduces mTORC1 activity in 
hippocampus and impairs memory formation 
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INTRODUCTION 
 
Proper translational control through the mechanistic Target of Rapamycin 
Complex 1 (mTORC1) is required for normal expression of synaptic plasticity and 
long-term memory (LTM) formation.  mTORC1 integrates signals from many different 
cellular inputs to regulate growth.  When mTORC1 is active, it phosphorylates S6 
protein kinase (S6K), which in turn phosphorylates ribosomal protein S6 (S6) and 
eukaryotic initiation factor 4B (eIF4B) to activate translation (26, 160).  These events 
have been shown to also occur in dendrites, placing mTORC1 at a critical location for 
translation-dependent synaptic plasticity (182, 183). 
Rapamycin, a selective inhibitor of mTORC1, impairs several plasticity related 
events like late-phase long-term potentiation (L-LTP) induced by high frequency 
stimulation, synaptic potentiation induced by BDNF, and metabotropic glutamate 
receptor-dependent long-term depression expression in hippocampal slices (74, 179, 
183).  This same drug has been shown to block hippocampal long-term memory 
formation in the Morris water maze task, the object recognition memory task, and 
reconsolidation of inhibitory avoidance memory (31, 87, 88).  Rapamycin infused in the 
auditory cortex of Mongolian gerbils blocks consolidation of differential conditioning to 
linearly frequency-modulated tones (188).  When infused in the amygdala or medial 
prefrontal cortex it inhibits delayed and trace fear conditioning memory respectively 
(149, 180).  These results suggest that mTORC1 regulated protein synthesis is 
required for normal long-term synaptic plasticity.   
The TSC1/2 complex lies upstream of mTORC1 and acts as a point of 
convergence for growth factors, hormones and ATP availability signals (36, 81).  
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Supporting the idea that mTORC1 activity is required for LTM, when these pathways 
are compromised, LTM is also inhibited.  For example, blocking BDNF activity in the 
rat dorsal hippocampus inhibits mTORC1 activation and impairs inhibitory avoidance 
LTM (175).  It has also been shown that insulin is capable of inducing Long-term 
depression (LTD) and rapamycin inhibits insulin-dependent dendritic spine formation 
(77, 115).  Lastly, glucose increases phosphorylation of mTORC1 downstream targets 
by inhibiting AMP kinase (AMPK), and enhancing LTM.  Furthermore, AMPK activators 
such as AICAR, 2-Deoxy-D-glucose and metformin, repress mTORC1 activity and 
block LTP and LTM expression (31, 157).  This suggests that mTORC1 integrates 
these intracellular and extracellular signals to regulate protein translation required for 
neuronal plasticity and long-term memory. 
Unlike growth factors, hormones and ATP, amino acids regulate mTORC1 
signaling through a pathway independent of TSC1/2.  The mechanism by which amino 
acids (leucine in particular) signal to mTORC1 is not well understood, although the 
leucyl-RNA synthetase, class III phosphatidylinositol (PI) 3-kinase-Vps34, Ras-related 
(Rag) guanosine triphosphatases (GTPases) and mitogen-activated protein kinase 
kinase kinase kinase 3 (MAP4K3) have all been implicated (62, 101).  In vitro studies 
have shown that removing amino acids impairs mTORC1 signaling.  When these are 
added back into the cell culture individually, phosphorylation of mTORC1 targets 
increases, with the strongest effect seen with leucine (33, 65, 82, 198).  Leucine is the 
best-studied mTORC1-activating amino acid, it alone can stimulate muscle protein 
synthesis, and when infused into the rat brain it increases hypothalamic mTORC1 
activity and decreases food intake and body weight (27, 159).  In vitro administration of 
glutamine, on the other hand, has produced variable results.  Some studies suggest 
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that glutamine inhibits mTORC1 signaling, others report that glutamine’s mTORC1 
inhibitory effect can be antagonized by leucine and yet other studies have found no 
difference in mTORC1 activity (33, 138, 142, 164).  The variability in these results 
could be explained by a recent finding by Nicklin et al.  When cultured cells are amino 
acid starved, addition of essential amino acids alone had very little effect on mTORC1 
activity.  However, when essential amino acids together with glutamine were added, 
mTORC1 activity was significantly increased.  Investigations on how amino acids enter 
the cell suggest that the glutamine transporter SLC1A5 is responsible for increases 
intracellular glutamine.  This glutamine is then exchanged for leucine through the 
SLC7A5 amino acid bidirectional anti-porter.  Therefore, glutamine can indirectly 
activate mTORC1 by facilitating leucine transport into the cell.  It is still unclear why an 
excess of glutamine could inhibit mTORC1.  While these studies have been carried out 
in amino acid deprived cells in culture, it remains unclear if glutamine can be used to 
modulate mTORC1 signaling in the in-vivo brain in order to influence cognition. 
My hypothesis is that if glutamine can inhibit mTORC1 activity in vivo, then 
glutamine will impair memory formation.  To test this hypothesis I completed the 
following specific aims: 
I. In vitro studies have shown that glutamine impairs mTORC1 activity of 
starved cultured cells (33, 138).  Therefore I sought to determine if 
glutamine could modulate the levels of phospho-S6 in non-starved cultured 
cells.  Consequently, I tested whether intra-hippocampal infusions of 
glutamine would decrease phospho-S6, indicating mTORC1 inhibition in 
vivo.   
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II. Inhibition of mTORC1 with rapamycin impairs long-term memory formation 
in a variety of behavioral tasks (18, 31, 87, 88, 188).  Therefore, I 
investigated the possibility that intra-hippocampal infusions of glutamine 
would impair long-term memory in the Morris water maze and fear context 
discrimination.   
III. It is possible that glutamine’s effect on mTORC1 signaling is through an 
indirect path by facilitating leucine access into the cell (140).  Since 
glutamine and leucine have opposite effects on mTORC1 activity, one would 
expect that co-administration of both amino acids would have a differential 
effect than applying glutamine alone (33, 82, 138).  For example, the effect 
of one amino acid could win over the other or their effects would cancel 
each other out.  Therefore, I investigated the effect of intra-hippocampal co-
adminitration of glutamine and leucine on the levels of phospho-S6 and 
long-term memory formation. 
 
GLUTAMINE REDUCES mTORC1 ACTIVITY IN VIVO 
 
Cell culture studies have shown that amino acids can regulate mTORC1 
signaling under starvation or amino-acid free conditions (33, 82).  However, starvation 
conditions are not optimal when training and testing animals for cognitive tasks.  For 
this reason, I first tested if glutamine can influence on mTORC1 activity in bEnd.3 cells 
under normal serum conditions.  bEnd.3 cells are brain derived endothelial cells and 
as such would be one of the first barriers for passage for molecules into the brain.  To 
determine if glutamine can affect mTORC1 signaling, bEnd.3 cells were normally 
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grown until confluence.  After reaching confluence, cells were pre-incubated for 2 hrs 
with serum-free DMEM lacking glutamine or normal media, and then stimulated with 
different concentrations of glutamine for 30 min.  Under serum-free conditions, 5 mM 
glutamine is sufficient to decrease the phosphorylation levels of the mTORC1 target 
S6K (33).  Consistently, my results using bEnd.3 cells show that under starvation 
conditions, 5 mM glutamine decreases the phosphorylation of S6K and S6 levels (Fig 
4.1A and B).  However, when cells are kept in normal growth conditions, 5 mM 
glutamine is unable to alter mTORC1 signaling.  In order to determine if starvation is 
necessary to influence mTORC1 activity, I performed dose-response studies using 
increasing amounts of glutamine.  Decreased phosphorylation levels of S6K and S6 
were observed at 40 mM glutamine under normal serum culture conditions (Fig 4.1C 
and D).  This suggests that high concentrations of glutamine can potentially be used in 
vivo to regulate mTORC1 signaling in the absence of food or amino acid deprivation. 
Next, I investigated the ability of glutamine to decrease mTORC1 activity in 
vivo.  I performed targeted infusions aimed at the dorsal hippocampus.  Rats were 
infused with 1.3 µl of a 194 mM (37 µg) solution of glutamine into one dorsal 
hippocampus and an equal volume of saline was administered simultaneously to the 
contralateral dorsal hippocampus of the same animal.  This dose was chosen based 
on my previous experiment which suggested that high concentrations of glutamine 
were necessary to affect mTORC1 activity in non-starved brain-derived cultured cells 
(Fig 4.1).  At 30 min after the completion of the infusion, rats were decapitated and the 
hippocampi isolated and homogenized for high-performance liquid chromatography  
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Figure 4.1: In vitro application of glutamine decreases phosphorylation of mTOR 
targets in starved and non-starved bEnd.3 cells.  At the top of each figure 
representative western blot samples are shown.  A and B) bEnd.3 cells under 
starvation conditions for 2 hrs were treated with 0 mM or 5 mM glutamine, and lysates 
collected 30 min later.  Glutamine administration significantly decreased mTOR 
targets, S6K (A, 2-tailed, unpaired student’s t-test; p<0.018) and S6 (B, 2-tailed, 
unpaired student’s t-test; p=0.042), phosphorylation but not their total protein levels.  C 
and D) bEnd.3 cells under normal culture conditions were treated with 0 mM, 5 mM or 
40 mM glutamine, and lysates collected 30 min later.  40 mM, but not 5 mM, glutamine 
treatment significantly decreased mTOR targets, S6K (C, One-way ANOVA 
F(2,6)=9.048, p<0.015) and S6 (D, One-way ANOVA F(2,6)=9.406, p=0.014), 
phosphorylation.  Total protein levels did not change significantly.  Data represent 
means ± s.e.m of immunoreactivity percentage corrected against β-actin loading 
control, *p<0.05. 
 
(HPLC) and western blot analysis.  Figure 4.2A shows that glutamine content is 
increased 2.5 fold in hippocampal tissue extracts 30 min after infusion.  Importantly, 
glutamate, a prominent excitatory neurotransmitter that can be synthesized from 
glutamine, did not show any changes at the time tested.  Figure 4.2B and 1C show 
representative Western blots and summary data indicating that glutamine infusion 
caused a significant decrease in the phosphorylation, but not the total levels, of S6 
(Fig 4.2C).  The phosphorylation levels of S6K trended down but did not reach 
statistical significance (Fig 4.2B).  To discard the possibility that non-specific, 
generalized effects were responsible for this result, I tested the samples for 
phosphorylation levels of upstream protein regulators of mTORC1 signaling.  
Phospho-Tsc2, phospho-AMP activated protein kinase and phospho-mitogen activated 
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protein kinase levels were not affected after glutamine administration (Fig 4.3).  These 
results indicate that glutamine can be used to manipulate mTORC1 activity in vivo. 
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Figure 4.2: In vivo Intrahippocampal administration of glutamine decreases mTOR 
activity.  A) Intrahippocampal infusions of glutamine (52 μg/hippocampus, n=3) or 
vehicle (saline) were administered and brain extracts collected 30 min later to be 
analyzed by HPLC.  Glutamine administration significantly increased its brain levels (2-
tailed, unpaired student’s t-test; p=0.008) but not the levels of glutamate (2-tailed, 
paired student’s t-test; p=0.14).  B and C) Intrahippocampal infusions of glutamine (37 
μg/hippocampus, n=6) or vehicle (saline) were administered and samples collected 30 
min later.  Glutamine administration significantly decreased mTOR target S6 
phosphorylation (C, 2-tailed, paired student’s t-test; p=0.049) but not its total protein 
level.  Phosphorylation levels of S6K (B, 2-tailed, paired student’s t-test; p=0.16) 
trended downward but did not reach significance.  To the left of each figure 
representative western blot samples are shown.  Western blot graphs show 
quantification corrected against β-actin loading control.  Data represent means ± 
s.e.m, *p<0.05. 
 
 
 
87 
 
 
 
Figure 4.3:  Intrahippocampal administration of glutamine does not affect the levels of 
pTSC2, pAMPK or pMAPK.  Intrahippocampal infusions of glutamine (37 
μg/hippocampus, n=6) or vehicle (saline) were administered and samples collected 30 
min later.  Glutamine administration did not significantly affect the phosphorylation 
levels of upstream mTORC1 signaling proteins TSC2 and AMPK or MAPK. 
 
GLUTAMINE IMPAIRS SPATIAL AND CONTEXTUAL MEMORY 
 
Agents known to inhibit the mTORC1 pathway, like Rapamycin, have been 
shown to impair long-term memory.  Consistent with in vitro studies, my findings 
suggest that high levels of brain glutamine can cause a decrease in mTORC1 activity, 
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as indicated by reduced phosphorylation of downstream targets (Fig 4.2C).  
Consequently, I posit that increasing brain glutamine may impair LTM.  I performed the 
hidden platform version of the Morris water maze task to test this prediction.  Animals 
were trained and immediately after reaching criterion (three consecutive trials <10 s), 
were infused bilaterally with 37 µg/hippocampus glutamine (n = 7) or an equal volume 
of vehicle (n = 8).  When tested for long-term memory in a retention test 48 h after 
training, the glutamine-treated group showed no difference in latency to the original 
platform location but crossed the platform location significantly fewer times (glutamine 
0.74 ± 0.18 crossings; vehicle 1.87 ± 0.44 crossings, p = 0.038) (Fig 4.4A and B).  This 
suggests that the glutamine-infused animals had an impaired memory of the platform 
location.  In addition to the number of crossings to the platform location, a significant 
interaction of group by location was detected between the two groups in the time spent 
in concentric circles of decreasing diameter centered around the platform location 
(F(3,36)= 5.015, p = 0.005).  Post-hoc analysis revealed that this interaction was due to 
the vehicle-infused animals spending more time in the immediate vicinity of the 
platform, whereas glutamine-infused animals searched in a wider area further from the 
platform (indicated by *, Fig 4.4D).  This is visually shown by representative traces of 
the swimming paths taken by a glutamine-treated animal and a vehicle-treated animal 
during the probe test (Fig 4.4C).  These differences were not attributable to changes in 
swimming speed (Fig 4.4E) or visual/motivational impairments (Fig 4.4F).  These 
results were reproduced with an even stronger impairment of LTM when 52 
µg/hippocampus glutamine was infused (Fig 4.5).  When animals infused with 52 
µg/hippocampus glutamine were tested for long-term memory in a retention test 48 h 
after training, the glutamine-treated group showed a significant difference in latency to  
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Figure 4.4: Post-training intrahippocampal administration of glutamine (37 µg) impairs 
long-term spatial memory.  A) Rats were trained in a 1-day Morris Water Maze 
protocol and infused with either vehicle solution (n=8) or 37 μg/hippocampus of 
glutamine (n=7) immediately after the last training trial.  A probe trial was given 48 hrs.  
later. Latency to locate the hidden platform is shown, (2-tailed, unpaired student’s t-
test; p=0.5).  B) The number of crossings of the previous platform location during the 
probe trial is shown, (2-tailed, unpaired student’s t-test; p=0.038).  C) Representative 
probe trial traces of a vehicle and a glutamine-infused animal showing the path taken.  
D) Dwell time in counter areas of decreasing diameters (4X, 3X and 2X platform 
radius) during the probe trial, (two-way repeated-measures of ANOVA with treatment 
and ring number as between-subjects factors: F(3,36)=5.015, p=0.005).  E) Swim 
velocity, (2-tailed, unpaired student’s t-test; p=0.9).  F) Latency to a visual platform 
performed after the probe trial, (2-tailed, unpaired student’s t-test; p=0.6).   
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Figure 4.5: Post-training intrahippocampal administration of glutamine (52 μg) impairs 
long-term spatial memory.  A) Rats were trained in a 1-day Morris Water Maze 
protocol and infused with either vehicle solution (n=9) or 52 μg/hippocampus of 
glutamine (n=8) immediately after the last training trial.  A probe trial was given 48 hrs.  
later, latency is shown, (2-tailed, unpaired student’s t-test; p=0.04).  B) A probe trial 
given 48 hrs.  later, number of crossings is shown, (2-tailed, unpaired student’s t-test; 
p=0.03).  Inset: Representative probe trial traces of a vehicle and a glutamine-infused 
animal during probe trial 2 showing the path taken.  C) Number of entries to counter 
areas of decreasing diameters (4X, 3X and 2X platform radius) during the probe trial, 
(two-way repeated-measures of ANOVA with treatment and ring number as between-
subjects factors: group main effect F(1,15)=8.412, p=0.011).  D) Dwell time in counter 
areas of decreasing diameters (4X, 3X and 2X platform radius) during the probe trial, 
(two-way repeated-measures of ANOVA with treatment and ring number as between-
subjects factors: group main effect F(1,15)=10.052, p=0.006).  E) Latency to counter 
areas of decreasing diameters (4X, 3X and 2X platform radius) during the probe trial, 
(two-way repeated-measures of ANOVA with treatment and ring number as between-
subjects factors: group main effect F(1,15)=4.818, p=0.044).  F) Swim velocity during 
probe trial 2, (2-tailed, unpaired student’s t-test; p=0.5).  G) Latency to a visual 
platform performed after probe trials, (2-tailed, unpaired student’s t-test; p=0.36).  
*p<0.05, **p<0.01, †p<0.05, ‡p<0.01.  Data represent means ± s.e.m. 
 
the original platform location (glutamine 56.1 ± 3 latency; vehicle 34.6 ± 8.7 latency, p 
= 0.04) (Fig 4.5A), and crossed the platform location significantly fewer times 
(glutamine 0.9 ± 0.2 crossings; vehicle 0.25 ± 0.16 crossings, p = 0.03) (Fig 4.5B).  
This support the previous finding, that the glutamine-infused animals had an impaired 
memory of the platform location.  In addition, a significant group main effect was 
detected between the two groups in the number of entries (Fig 4.5C), time spent (Fig 
4.5D) and latency (Fig 4.5E) to concentric circles of decreasing diameter centered 
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around the platform location (entries, F(1,15)=8.412, p=0.011; dwell time 
F(1,15)=10.052, p=0.006; latency F(1,15)=4.818, p=0.044).  Post-hoc analysis 
revealed that this group difference was due to the vehicle-infused animals spending 
more time in the immediate vicinity of the platform, whereas glutamine-infused animals 
searched further from the platform (indicated by *, Fig 4.5C, D and E).  This is visually 
shown by representative traces of the swimming paths taken by a glutamine-treated 
animal and a vehicle-treated animal during the probe test (Fig 4.5B inset).  These 
differences were not attributable to changes in swimming speed (Fig 4.5F) or 
visual/motivational impairments (Fig 4.5G). 
To further confirm that intra-hippocampal glutamine infusions have a detrimental effect 
on LTM, rats were trained in a contextual delayed fear conditioning task.  Animals 
were presented with a tone for 30 seconds at the end of which they received a 2 s-0.8 
mA shock.  They were given 3 trials separated by 1 min in the training chamber.  
Immediately after training the rats were infused with 37 µg/hippocampus glutamine (n 
= 11) or an equal volume of vehicle (n = 9).  There was no difference in baseline 
freezing between the two groups (Fig 4.6A left).  Memory was tested 48 h after 
training; there was no difference between the groups when they were exposed to the 
training tone, a hippocampus independent memory (Fig 4.6A right).  When tested for 
contextual memory, the two groups displayed similar freezing behavior in the training 
chamber (Fig 4.6B left).  However, when fear was assessed in a novel context that 
shared similar features with the training cage while differing in others, the glutamine-
infused animals displayed a significantly higher freezing behavior than the vehicle 
infused animals (glutamine 24.14 ± 4.35 % freezing; vehicle 7.28 ± 1.72 % freezing, p 
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= 0.004) (Fig 4.6B right).  This suggests that glutamine-infused rats had problems 
distinguishing between the two chambers. 
 
 
Figure 4.6: Post-training intrahippocampal administration of glutamine (37 µg) impairs 
long-term contextual fear memory.  Rats were trained in a delay fear conditioning 
paradigm and infused with either vehicle solution (n=9) or 37 μg/hippocampus of 
glutamine (n=11) immediately after the last training trial.  A test was given 48 hrs.  
later.  A) Left, % time freezing is shown for baseline conditions (2-tailed, unpaired 
student’s t-test; p=0.4).  Right, % time freezing in a completely different novel context 
and exposed to the training tone (2-tailed, unpaired student’s t-test; p=0.6).  B) Left, % 
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time freezing in the training context (2-tailed, unpaired student’s t-test; p=0.3).  Right, 
% time freezing in a novel but similar context (2-tailed, unpaired student’s t-test; 
p=0.004).  Data represent means ± s.e.m., *p<0.05, **p<0.01. 
 
CO-ADMINISTRATION OF LEUCINE WITH GLUTAMINE REVERSES GLUTAMINE 
ALONE EFFECTS 
 
Intra-hippocampal leucine increases mTORC1 activity but has no effect on memory 
formation 
 
Previous studies have shown that leucine can activate mTORC1 in vitro, and 
that brain infusions of leucine in fasted rats can also increase mTORC1 signaling (27, 
82).  To determine if leucine can activate hippocampal mTORC1 in non-fasted rats, I 
infused 1.5 µl of a 137 mM solution (27 µg) of leucine into one dorsal hippocampus 
and an equal volume of saline was administered simultaneously to the contralateral 
dorsal hippocampus of the same animal.  Figure 4.7A and 3B show representative 
western blots and summary data indicating that a significant increase in the 
phosphorylation, but not the total levels, of the translational regulators S6K and S6 
was detected when leucine was administered. 
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Figure 4.7: Intrahippocampal administration of leucine increases mTOR activity.  
Intrahippocampal infusions of leucine (27 μg/hippocampus, n=5) or vehicle (saline) 
were administered and samples collected 30 min later.  A) Leucine administration 
significantly increased phosphorylation of mTORC1 target, S6K (A, 2-tailed, paired 
student’s t-test; p=0.03) B) Leucine administration significantly increased 
phosphorylation of mTORC1 target S6 (B, 2-tailed, paired student’s t-test; p=0.01), but 
not their total protein levels.  Data represent means ± s.e.m., *p<0.05. 
 
Based on the results obtained in the previous experiment, it was anticipated 
that leucine, via activation of mTORC1, would cause an improvement in memory.  To 
test this possibility, rats were trained in the hidden platform version of the Morris water 
maze.  Immediately after reaching criteria the rats were infused with 13 
µg/hippocampus leucine (n = 10; supplemental Fig 4.8A and B), 27 µg/hippocampus 
leucine (n = 10; Fig 4.8 C and D) or an equal volume of vehicle (n = 11).  When they 
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were tested for LTM during a retention test 48 h after training, there was no difference 
between the amino acid- and vehicle-infused animals (leucine 13 µg 35.6 ± 4 latency, 
1.45 ± 0.3 crossings  ; vehicle 37.2 ± 4 latency, 1.5 ± 0.4, p = 0.6), (leucine 27 µg 16.6 
± 7 latency, 1.7 ± 0.3 crossings; vehicle 28.5 ± 6 latency, 2.1 ± 0.3, p=0.7 and p = 0.18 
latency and crossings respectively) (Fig 4.8).  No difference was also observed when a 
less robust training criterion (three consecutive trials with an average of <15 s platform 
latency) was used (data not shown), one that has been previously used for agents that 
enhance LTM (31), suggesting that a possible transient increase in mTORC1 activity 
induced by leucine has no effect on LTM. 
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Figure 4.8: Post-training intrahippocampal administration of leucine has no effect on 
long-term spatial memory.  A) Rats were trained in a 1-day Morris Water Maze 
protocol and infused with either vehicle solution (n=11) or 13 μg/hippocampus of 
leucine (n=10) immediately after the last training trial.  A probe trial was given 48 hrs.  
later, latency to cross the previous location of the platform is shown, (2-tailed, unpaired 
student’s t-test; p=0.6).  B) A probe trial given 48 hrs.  later, number of crossings of the 
previous platform location is shown, (2-tailed, unpaired student’s t-test; p=0.6).  C) 
Rats were trained in a 1-day Morris Water Maze protocol and infused with either 
vehicle solution (n=11) or 27 μg/hippocampus of leucine (n=10) immediately after the 
last training trial.  There was no difference in a probe trial given 48 hrs.  later, latency 
is shown, (2-tailed, unpaired student’s t-test; p=0.7).  D) There was no difference in 
number of crossings during the probe trial, (2-tailed, unpaired student’s t-test; p=0.18).  
E) Left, representative schematics showing intrahippocampal infusion sites (black 
dots).  Right, representative picture of cannula placement.  Data represent means ± 
s.e.m. 
 
Glutamine effects can be overcome by co-administration with leucine 
 
As my results show that leucine and glutamine have opposing influences on 
mTORC1 activity, I tested the effect of co-infusion of these amino acids.  To determine 
the effect of co-administration of leucine and glutamine on mTORC1 signaling, 30 min 
post-infusion extracts were compared to the contralateral hippocampi infused with 
vehicle.  Figure 4.9A and B show representative western blots and summary data 
demonstrating that when leucine and glutamine are co-infused, there is no effect on 
mTORC1 activity.  As indicated by no change in the phosphorylation levels of S6K and 
S6. 
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Figure 4.9: Intrahippocampal co-administration of leucine and glutamine blocks effects 
of single amino acid infusion on mTOR activity.  A and B) Intrahippocampal co-
infusions of leucine and glutamine (27μg/hippocampus, 52 μg/hippocampus 
respectively, n=5) or vehicle (saline) were administered and samples collected 30 min 
later.  There was no significant effects in the levels of pS6K or total S6K (C, 2-tailed, 
paired student’s t-test; p=0.8, p=0.4, respectively).  There were no significant effects 
on the levels of pS6 or total S6 (D, 2-tailed, paired student’s t-test; p=0.6, p=0.9, 
respectively).  Data represent means ± s.e.m. 
 
To determine whether the lack of an effect on mTORC1 activity when leucine 
and glutamine are co-infused into the hippocampus also affected the behavioral 
outcome, I again performed the Morris water maze task.  Animals were trained and 
immediately after reaching criterion (three consecutive trials <10 s), were infused 
bilaterally with 27 µg leucine and 52 µg glutamine/hippocampus (n = 9) or an equal 
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volume of vehicle (n = 9).  When they were tested for long-term memory in a retention 
test 48 h after training, the amino acid-treated group showed no difference in latency 
to the original platform location or the number of times it crossed the platform location 
(amino acids 29.3 ± 10.4 latency; vehicle 34.6 ± 8.7 latency, p = 0.7 and amino acids 
1.4 ± 0.56 crossings; vehicle 1 ± 0.2 crossings, p = 0.5) (Fig 4.10A and B).  Further 
analysis revealed that both groups of animals developed a similar search pattern.  This 
is shown by their time spent in counter areas of decreasing diameter around the 
platform location (F(3,48)= 0.663, p = 0.579) (Fig 4.10C).  This suggests that when both 
amino-acids are increased in the brain, mTORC1 activity is not altered and LTM is not 
altered.  After completion of the behavioral testing, animals were killed and their brains 
were analyzed for infusion site accuracy.  Fig 4.10D shows the locations of the 
intrahippocampal infusion sites for representative animals used in the Morris water 
maze study. 
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Figure 4.10: Post-training intrahippocampal co-administration of leucine and 
glutamine blocks effects of single amino acid infusion on long-term spatial memory 
formation.  A) Rats were trained in a 1-day Morris Water Maze protocol and infused 
with either vehicle solution (n=9) or 27μg/hippocampus of leucine and 
52μg/hippocampus of glutamine (n=9) immediately after the last training trial.  There 
was no significant difference in a probe trial given 48 hrs.  later, latency is shown, (2-
tailed, unpaired student’s t-test; p=0.7).  B) There was no difference in number of 
crossings during the probe trial, (2-tailed, unpaired student’s t-test; p=0.5).  C) Dwell 
time in counter areas of decreasing diameters (4X, 3X and 2X platform radius) during 
the probe trial, (two-way repeated-measures of ANOVA with treatment and ring 
number as between-subjects factors: interaction F(3,48)=0.663, p=0.579).  D) 
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Representative schematics showing intrahippocampal infusion sites (black dots).  Data 
represent means ± s.e.m. 
 
SUMMARY AND DISCUSSION 
 
The findings from the present study demonstrate for the first time the 
association between glutamine effects on brain mTORC1 regulation and long-term 
memory.  Specifically, I show that the amino acid glutamine impairs long-term 
memory, an effect that can be mitigated by co-administration of the branch-chain 
amino acid leucine.  These behavioral consequences are consistent with the 
influences of these amino acids on the mTORC1 pathway, and suggest that leucine 
and/or glutamine supplementation may have value in conditions associated with 
mTORC1 misregulation.   
In vitro studies have shown that mTORC1 activity responds to the availability of 
amino acids.  Specifically, cell culture studies have demonstrated that removal of 
amino acids causes suppression in mTORC1 activity that can be reverse by addition 
of branched chain amino acids, with the more potent effects observed following 
leucine application.  Glutamine, by comparison, has been demonstrated to reduce 
mTORC1 activity or block the influence of leucine depending on the cell type 
examined.  However, glutamine also plays an important role in the activation of 
mTORC1 aiding in the entry of leucine into the cell (140).  Although systemic 
administration of leucine has been shown to enhance mTORC1 activity in skeletal 
muscle, there has been only one study indicating that leucine infusions into the brain 
can activate this pathway (27, 33, 65, 82, 138, 159, 164).  In all of these studies, the 
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cells or animals were starved or food restricted prior to the treatment.  No studies have 
been published addressing in vivo glutamine modulation of mTORC1.  As food 
deprivation and dietary restrictions have been shown to influence cognitive function, I 
questioned if glutamine could influence mTORC1 activity in brains of normally fed rats 
(66, 143).  I observed that intrahippocampal infusions of leucine enhanced, while 
glutamine inhibited, mTORC1 activity.  When administered concurrently, no influence 
on mTORC1 activity was detected.  This is the first report to indicate that 
administration of amino acids to non-food deprived animals can be used to modulate 
mTORC1, supporting their use as nutritional supplements. 
 My results show that high concentrations of glutamine, when infused directly 
into the brain, inhibit mTORC1 activity and impair both long-term spatial and 
contextual memory.  Glutamine is very abundant in the brain where it acts as a 
precursor for neurotransmitters like glutamine and GABA (6, 197).  It is possible that 
the effects I observed on LTM, as a result of glutamine administration, were due to an 
increase in the levels of these neurotransmitters.  However, when samples obtained 
from glutamine-infused rats were assessed for glutamate levels, no significant 
differences were observed.  Further, the memory impairment seen following glutamine 
administration was not observed in rats co-administered leucine, an effect not 
expected if glutamine altered GABA levels.  Although the reason for this apparent 
opposite effects is not clear, it has been suggested that glutamine may regulate 
leucine availability.  Therefore, an imbalance in the concentrations of these two amino 
acids may be responsible for the changes in mTORC1 activity I observed (140).   
It was expected that leucine would enhance memory formation due to its effect 
on increased mTORC1 activity.  Contrary to this prediction, leucine had no effect on 
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long-term spatial memory formation.  This result suggests that even though this amino 
acid was able to upregulate mTORC1, this effect was not sufficient to alter long-term 
memory.  Previous studies have suggested that high levels of brain leucine are 
detrimental to memory formation.  For example, using a model of Maple syrum urine 
disease in which the branched-chain amino acids -leucine, isoleucine and valine- were 
administered subcutaneously twice daily for 21 days, Scaini et al.  reported impaired 
habituation in the open field task and disturbed object recognition memory.  The 
authors of this study observed that chronic leucine caused a persistent increase in 
BDNF levels, which is thought to accelerate excitotoxic neuronal necrosis (169).  
Using intra-hippocampal administration of leucine (10.5 µg), Glaser et al.  reported 
impaired long-term memory in a step-down task, an effect associated with changes in 
mitochondrial function (56).  Taken together, these findings suggest that changes in 
brain leucine concentrations may have differential effects on LTM depending on 
treatment length and the behavioral task performed. 
In conclusion, the results presented in this chapter suggest that the amino acids 
glutamine and leucine act as signaling molecules to regulate the mTORC1 pathway 
and could potentially be used as dietary supplementations in disorders in which 
mTORC1 is misregulated.   
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CHAPTER 5 
Oral glutamine extends survival of Tsc2 
conditional knock-out mice 
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INTRODUCTION 
 
The importance of the TSC-mTORC1 pathway in LTM is clearly evident when 
its disruption results in neurological disorders.  These disorders include 
neurofibromatosis type 1, PTEN associated macrocephaly, Fragile X syndrome and 
Tuberous Sclerosis Complex (TSC) (109, 116, 139).   
Increased mTORC1 activity, resulting from either loss of TSC1 or TSC2 
proteins, results in TSC, an autosomal dominant disorder (19, 29).  Patient population 
studies have shown that TSC2 gene mutations account for 60% of TSC patients, while 
only 30% express TSC1 mutations (90, 91).  Some studies have reported that patients 
with a mutation in TSC2 have more severe neurological pathologies than patients with 
TSC1 mutations.  A recent study comparing Tsc1 and Tsc2 conditional knock-out mice 
supports this view.  Even though the mechanistic basis for this difference is not known, 
one could hypothesize that since tuberin contains the GTPase activating protein 
domain of the TSC molecular complex, then mutations in Tsc2 would have more 
severe phenotypes than mutations in Tsc1 (207).   
Heterozygous mouse models lacking Tsc1 or Tsc2 eventually manifest renal 
tumors but have no major central nervous system pathologies, which are the main 
cause of morbidity and mortality in TSC patients.  Homozygous Tsc1 or Tsc2 mice are 
embryonic lethal (71, 105, 106).  To better understand how TSC causes brain 
abnormalities that result in seizures and learning and behavioral deficits, conditional 
homozygous brain disruptions of Tsc1 and Tsc2 have been developed.  Genetic 
mouse models that affect developmental stages have severe phenotypes including 
megancephaly, cortical and hippocampal lamination defects, enlarged dysplastic 
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neurons and glia, abnormal myelination and astrocytosis.  These mice die within 1-2 
months of being born (28, 191, 200, 207).  Conditional mouse models using the 
CamK2a promoter driven Cre recombinase bypass the embryonic and developmental 
stages and present less severe brain pathologies.  For example, Tsc1flox/flox;CamK2a-
cre mice have enlarged brains due to massive neuronal hypertrophy and present 
astrogliosis.  Behaviorally they show an abnormal hindlimb clasping reflex and are 
hypoactive compared to control littermates.  These mice also die within their first 3 
months of age (41).   
Rapamycin and other mTORC1 inhibitors are being studied as potential 
treatments for misregulated mTOR-driven disorders (15, 42, 49).  For example, the 
lethality observed in mouse models of TSC can be mitigated by daily administration of 
rapamycin (201) and its use for the treatment of subependymal giant cell astrocytomas 
associated with TSC has been approved by the Federal Drug Administration (48).  
Thus, identification of additional agents that can regulate mTORC1 activity in vivo may 
have both basic science and translational value. 
In the previous chapter I showed that glutamine can impair long-term memory 
formation when infused into the hippocampus and this is correlated with a decrease in 
mTORC1 activity.  My hypothesis is that if in vivo administration of glutamine can 
inhibit mTORC1 signaling, then it could be used to extend life in Tsc2flox/flox;CamK2a-
cre  (Tsc2CKO) mice.  To test this hypothesis I completed the following specific aims: 
I. Although the blood brain barrier is designed to remove glutamine from the 
brain, studies show that high concentrations of oral glutamine increase brain 
glutamine levels (67, 197).  In addition, I have shown that glutamine can 
decrease mTORC1 activity when infused into the hippocampus.  Therefore, 
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I aimed to evaluate the efficacy of oral glutamine to attenuate mTORC1 
signaling in Tsc2CKO mice hippocampi.   
II. Tsc1flox/flox;CamK2a-cre mice die within 3 months of age but treatment with 
rapamycin can decreased mTORC1 activity and extend their life span.  
Therefore, I tested the possibility that oral glutamine would extend lifespan 
of Tsc2CKO mice. 
 
CHARACTERIZATION OF TSC2FLOX/FLOX; CAMKIIA-CRE MICE 
 
Conditional knock-out mouse models of TSC show several brain pathologies as 
well as behavioral deficits (28, 41).  To assess the severity of brain and behavioral 
pathologies in Tsc2CKO mice, animals were monitored once daily.  Weight, physical 
appearance (coat appearance, nasal/ocular discharge, abnormal posture) and general 
behavior (hindlimb clasping reflex, reduced mobility, isolationism, mutilation, and 
restlessness) were recorded.  Tsc2CKO mice did not show any differences in weight 
gain (Fig 5.1B), coat appearance or any other physical attribute.  General cage 
behavior also appeared normal, animals were seen grooming, being groomed and no 
mobility impairments were noted.  Occasionally animals would react to manipulation 
with uncontrolled jumping, extreme movement of extremities and loud vocalizations; 
these events were noted as seizures.  Abnormal hindlimb clasping reflex was 
observed immediately before or after a seizure episode (Fig 5.1A) but was otherwise 
normal.  Finally, preliminary histological studies did not show any overt differences in 
neuronal size or lamination defects.  Tsc2CKO mice showed enhanced pS6 
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expression levels in the hippocampus when compared to control littermates and died 
within 3 months of age.   
 
 
 
Figure 5.1: Tsc2CKO mice hindlimb clasp and weight gain.  A) Tsc2CKO mice often 
show a hindlimb clasp (arrow) close to the beginning or after a seizure.  Top, control 
littermate mouse with normal reaction to being lift by the tail.  Middle and bottom, 
abnormal response, hindlimb clasp, indicative of neurological impairment.  B) There is 
no significant difference between Tsc2CKO mice and control littermates in weight gain.  
Data represent means ± s.e.m. 
 
ORAL GLUTAMINE REDUCES mTORC1 ACTIVITY AND EXTENDS SURVIVAL OF 
TSC2FLOX/FLOX; CAMKIIA-CRE MICE 
 
Genetic experimental models of tuberous sclerosis complex, like Tsc1 and Tsc2 
conditional knock-out mice, show elevated levels of mTORC1 activity due to the lack 
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of TSC-TBC complex repression.  Reducing mTORC1 activity with rapamycin 
improves their survival (Ehninger et al.  2008; Way et al.  2012).  The results 
presented in the previous chapter, suggest that glutamine has mTORC1 inhibiting 
properties as well and could potentially be used to treat diseases in which mTORC1 is 
misregulated, like TSC.  For this reason, Tsc2CKO mice of 1 month of age, were 
administered 3 g/kg glutamine (n=5) or an equal volume of saline (n=5) via gavage 
twice a day (morning and afternoon), 5 days per week for 2 weeks.  A third group of 
control littermates was used to establish normal levels of pS6.  At the end of the 2 
weeks and 1 h after the last dose, animals were killed and their brains removed to be 
fixed for immunohistochemistry.  Tissues probed with an antibody against 
phosphorylated S6 (Ser240/244) showed higher immunoreactivity in the hippocampus 
of vehicle treated mice, particularly the DG and CA1 regions when compared to control 
littermates (Fig 5.2 A first and second panels).  This was expected due to the lack of 
Tsc2, which results in over activation of mTORC1.  Interestingly, the glutamine treated 
samples show reduced phospho-S6 immunoreactivity in the DG, but not CA1, when 
compared to vehicle treated mice.   
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Figure 5.2: Oral glutamine decreases hippocampal mTORC1 activity in CamKII-Tsc2 
Conditional KO mice.  A) Representative samples showing CamKII-Tsc2 Conditional 
KO mice with increased mTORC1 activity in hippocampus than control littermates 
(Right first and second pictures).  This is most evident in CA1 and DG regions.  B) Oral 
administration of glutamine (3 g/kg twice daily) significantly decreases the 
phosphorylation levels of S6 in DG (Left top, One-way ANOVA F(2,11)=9.017, p=0.005) 
but not NeuN (Left bottom, One-way ANOVA F(2,11)=0.341, p=0.718).  Data represent 
means ± s.e.m. 
 
As Tsc2CKO mice die prematurely, I questioned if glutamine administration can 
improve survival, as has been seen with rapamycin.  Mice were treated with glutamine 
as described above (n=11 per group) until death was noted.  My results show that 
there was a statistical difference between the Kaplan-Meier survival curves of 
glutamine and vehicle treated animals (Fig 5.3B).  It can be observed that the lethal 
time at which 50% of the Tsc2CKO animals die (LT50) was prolonged by 
approximately 2 weeks in the glutamine treated group.  These results suggest that 
glutamine administration can lower mTORC1 activity in the dentate gyrus, as well as 
prolong the life span of Tsc2CKO mice. 
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Figure 5.3: Oral glutamine extends survival in CamKII-Tsc2 Conditional KO mice.  
Kaplan-Meier survival curves show how oral glutamine administration (3 g/kg twice 
daily) significantly extends survival of CamKII-Tsc2 Conditional KO mice (n=11/group, 
Log Rank test, p=0.044).  Dashed line indicated time at which 50% of animals die. 
 
SUMMARY AND DISCUSSION 
 
To the best of my knowledge, this is the first study indicating that oral glutamine 
treatments could be used to improve the morbidity and mortality of mTORC1 
associated disorders such as TSC.  In the previous chapter, I showed that intra-
hippocampal glutamine impairs long-term memory, an effect that can be reversed by 
co-administration of leucine.  These cognitive consequences, which are consistent 
with the influences of these amino acids on the mTORC1 pathway, suggest that 
leucine and/or glutamine supplementation may have value in conditions associated 
with mTORC1 misregulation.  Supporting this idea, I showed that oral glutamine 
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administration lowered mTORC1 activity levels of Tsc2CKO mouse brains and 
prolonged their life span. 
Animals were given 6 g/kg of daily glutamine based on the assumption that high 
levels of glutamine would be needed to influence mTORC1 signaling in the brain (see 
results from previous chapter). However, this amount of glutamine would be 
inconvenient for a human patient to consume on a daily basis (an average 85 kg 
person would need to consume 510 g of glutamine). Future studies should be done to 
determine the optimal glutamine dose and most efficient route of administration 
needed to decrease mTORC1 activity.  
Glutamine treatment has been shown to be effective in the recovery from 
trauma, cancer chemotherapy, alcohol withdrawal and has been used to treat Sickle 
Cell Anemia (5, 92, 141, 178).  The widespread metabolic roles of glutamine allows for 
its boundless effects.  For example, the rapid depletion of glutamine after catabolic 
stress caused by trauma, sepsis or burns makes it conditionally essential and its 
administration results in reduced rates of inflammation, infection, hospital stay and 
mortality (100).  Additionally, glutamine’s role in ammonia detoxification has made its 
synthesis and deamidation a target for the treatment of hepatic encephalopathy (92, 
161).  My results suggest a new role for glutamine as an mTORC1 inhibitor.  Tsc2CKO 
animals have higher levels of mTORC1 activity due to the lack of the mTORC1 
negative regulator complex TSC1-TSC2.  When these animals are given oral 
glutamine, mTORC1 activity is reduced and their life span is prolonged by about 2 
weeks.   
In vitro studies have shown that glutamine can influence mTORC1 signaling 
through either the Rag GTPases by facilitating leucine access into the cell or through 
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the AMPK-TSC1/2-Rheb pathway by entering the Krebs cycle after glutaminolysis 
(102).  These studies suggest that glutamine is necessary for mTORC1 activation.  
However, studies have shown that glutamine inhibits mTORC1 signaling in cultured 
cells (33, 138).  It seems that glutamine can either activate or inhibit mTORC1 
signaling depending on the concentration used.  An extension of this study would be to 
better define the amount of oral glutamine that could enhance, instead of inhibit, 
mTORC1 activation.   
The mTORC1 pathway has been implicated in several diseases including 
cancer, Alzheimer’s disease, Parkinson’s disease, and tuberous sclerosis complex 
amongst others (23).  My results suggest that manipulation of glutamine and leucine 
may have benefit in the treatment of these diseases due to their roles as mTORC1 
regulators.  Further studies will be required to fully explore these possibilities. 
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CHAPTER 6 
General discussion 
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SUMMARY OF FINDINGS AND FUTURE DIRECTIONS 
 
The ability of mTORC1 signaling to integrate nutritional, energy and stress 
signals to regulate cellular health and survival, make this pathway an important target 
for several diseases.  In this thesis, I have furthered our understanding of the role 
mTORC1 plays in memory formation and memory dysfunction.   
In Chapter 3, I showed that a heterozygous deletion of Tsc2 increases 
mTORC1 activity.  This increase in mTORC1 activity was not associated with either 
memory deficits or memory augmentation.  When mTORC1 activity was further 
elevated by a brain concussion, memory deficits became exacerbated when compared 
to injured Tsc2+/+ litter mates.  When mTORC1 levels returned to baseline five weeks 
after the injury, Tsc2+/KO mice cognitive performance was similar to Tsc2+/+ litter mates.  
My results indicate that acute elevation of mTORC1 activity is detrimental for brain 
injury-induced cognitive impairments.  This supports previous findings showing that 
acute inhibition of mTORC1 with rapamycin improved outcome after brain injury (44, 
147).  However, my results were not able to determine if elevated mTORC1, in 
Tsc2+/KO mice, would be beneficial in chronic stages after a closed head injury.   
Rapamycin and its derivatives are potent inhibitors of mTORC1.  The treatment 
of mTORC1 related disorders with these drugs has the disadvantage of potential over 
inhibition of mTORC1, which can have detrimental health effects (146, 206).  This led 
to the hypothesis that mTORC1 modulation with nutrients, such as amino acids, could 
more subtly produce changes in this pathway.  In chapters 4 and 5, I presented 
evidence indicating that glutamine can inhibit in vivo mTORC1 signaling, impairs LTM 
and extends the life span of Tsc2CKO mice.  Although the mechanism by which 
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glutamine exerts this action is not known, a correlation between its administration and 
mTORC1 reduction was shown, indicating that this pathway may, in part, explain 
glutamine’s effects.  These are important findings that support the idea that mTORC1 
could be modulated by designing a specific nutritional program.  Indeed, reducing 
mTORC1 signaling with rapamycin has been shown to extend lifespan in several 
organisms including mammals (46).  Likewise, dietary restriction in the absence of 
malnutrition is associated with extended longevity, increased stress resistance and 
improved metabolic fitness (51).  The effects of dietary restriction have been correlated 
with lower mTORC1 activity, suggesting that this pathway is involved in lifespan 
modulation and can be regulated through nutritional changes (89).  Whether an 
optimal range of mTORC1 activity exists that can extend lifespan and enhance 
memory is not known.   
Glutamine is a non-essential amino acid that becomes essential after trauma.  
Its administration can improve survival and diminish infectious complications in 
critically ill patients (5).  Future experiments should be designed to test whether 
glutamine can improve TBI outcome and if this improvement is associated with 
mTORC1 regulation.  TBI is associated with an acute hyperglycemic phase which 
coincides with MTORC1 increase following the concussion (8, 20, 174).  This is 
followed by an extended suppression of glucose metabolism that can be 
counterbalanced with sodium pyruvate treatments to improve outcome (50, 133, 134).  
Glutamine is indirectly involved in mTORC1 signaling modulation and energy 
production through the Krebs cycle (30, 102).  Consequently, I would expect glutamine 
to be beneficial in the treatment of TBI.   
 
120 
 
Taken together, my findings suggest that memory formation can function 
normally within a certain range of mTORC1 activation (Fig 6.1).  Previous studies have 
shown that rapamycin administration can decrease mTORC1 activity and impair LTM, 
and results from chapter 4 indicated that mTORC1 inhibition by glutamine 
administration produces a similar effect (18, 31, 188).  The results from chapter 3 
show that a further increase of mTORC1 signaling in Tsc2+/KO mice, after a closed  
 
 
 
Figure 6.1: Hypothetical range of mTORC1 activity and its modulation of LTM.  
MTORC1 inhibition with rapamycin impairs memory formation, suggesting that low 
levels of mTORC1 activity during consolidation can be detrimental for this process.  
On the other hand, high levels of mTORC1 activity might produce cognitive deficits, 
such as those seen in TSC patients.  Therefore, an optimal range of mTORC1 
activation should produce average (as seen in healthy individuals) cognition (red 
dotted curve).  Whether a fine tuning of mTORC1 activity within its optimal range can 
be achieved to improve cognition is not known (Green dotted curve). 
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head injury, impaired LTM in these animals. These results suggest that elevated 
mTORC1 signaling can also be detrimental for LTM.  This is further supported by the 
fact that TSC patients also suffer cognitive deficits.  
Although our understanding of the mechanisms by which mTORC1 is regulated 
is not fully understood yet, my results support the possibility that an optimal mTORC1 
activity range exists to successfully modulate LTM.  Whether LTM can be enhanced 
within this optimal range is still unclear. My results from chapter 3 show that elevated 
levels of mTORC1 activity in Tsc2+/KO mice had no effect on memory formation.  
However, it has been previously shown that intra-hippocampal infusions of glucose 
enhance LTM and increase mTORC1 signaling (31).  A better understanding of the 
mechanisms by which nutrients modulate mTORC1 would greatly aid in the design of 
treatments that can specifically target distinct pathways to finely tune mTORC1 
activity.  
 
 
. 
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